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ABSTRACT 
  Coronaviruses (CoVs) can cause a range of symptoms; from a mild common cold to life 
threatening acute respiratory distress syndrome (ARDS) upon infection. CoVs provide an 
example of the importance of studying emerging viruses. These emerging viruses have the ability 
to be highly pathogenic and detrimental to the human population. Two prime examples of CoV 
emergence, SARS-CoV (Severe Acute Respiratory Syndrome) and MERS-CoV, (Middle Eastern 
Respiratory Syndrome), which exhibits the pandemic potential of emerging CoVs that gain 
human tropism. This human tropism is gained through mutations that allow for cross species and 
zoonotic transmission. If there was an outbreak of an emerging CoV strain, not only would that 
be deleterious to human health but could potentially accumulate billions in health care costs to 
treat infected patients. Given the increasing potential of an emerging CoV outbreak, there needs 
to be a state of urgency to develop vaccines that will help protect the human population against 
current and future circulating strains. The Coronavirdae family of viruses are unique because 
they contain a highly conserved gene arrangement and function within its viral genome. The 
purpose of this study is to identify a technique that will allow the identification of attenuating 
mutations that are present within a functionally conserved region. By identifying conserved 
targets of attenuation, I can identify mutations that can be applied to the development of a CoV 
vaccine strain for one or more CoVs. Currently, there are many ways in which we can identify 
attenuating mutations, and one such way is to identify temperature-sensitive (TS) mutants. A TS 
mutant will be able to confer a wild type phenotype when incubated under permissive conditions 
and will confer an attenuated phenotype when incubated in non-permissive conditions.  By 
		 x	
chemically inducing mutations and then verifying mutations that confer a TS phenotype, I can 
identify mutants that contain TS mutations in their viral genome. By using genomic sequencing 
of these TS mutants, I am able to identify novel attenuating mutations in the CoV genome. TS  
phenotyping allows for the potential application of the attenuating mutation to current strains, 
and confer protection, but also identifies targets for mutation that may also attenuate future 
emerging CoVs.  The results gained from this study confirm the use of TS phenotyping and 
sequencing as an advantageous tool to identify sites that confer attenuation. With the proof that 
CoVs have the capability to mutate to gain human tropism, resulting in deadly disease, we must 
begin to prepare for potential pandemic outbreak.
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CHAPTER ONE 
BACKGROUND 
Literaure Review 
There has been an ongoing battle between humans and viruses since both have occupied 
the earth. As obligate intracellular pathogens, viruses have only two main focuses: replicate and 
disseminate. Humans, however, have developed methods to counteract these viral infections. Our 
bodies as living organisms have two main focuses as well: identify the pathogen and eliminate it. 
Typically, our bodies’ constantly adapting immune system has the ability to fight off viral 
infections by controlling the infection to keep them from causing major health issues. But there 
have been many examples in history in which viruses have won that battle causing major health 
issues. Within the last 100 years we have numerous documented examples of such viral success, 
such as the 1918 influenza outbreak resulting in millions of deaths1, Human Immunodeficiency 
Virus (HIV) also killing millions2, as well as SARS-CoV and MERS-CoV infections, which 
combined have killed thousands3,4. Although these RNA viruses are different in their 
characteristics they harbor, there is one common factor that aided their success to cause so much 
harm to the human population: un-anticipated emergence. When these viruses emerged from 
their host species into our naïve human population it resulted in the deaths of many. How can 
these pandemics be avoided one may wonder? The answer is simple: by studying emerging 
viruses and making vaccines that can protect against current and potentially emerging strains. 
One viral group that deserves such attention is coronaviruses, which in the last 15 years have had 
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two viral strains emerge into the human population with the potential to cause world-wide 
pandemics.
Coronavirus History and Classification. 
 CoVs were first isolated in 1965 from human organ cultures from the respiratory tract of 
an adult with a common cold. Byone and Tyrell et al. were able to determine the presence of an 
infectious agent by inoculating human volunteers with the media from these cultures, which 
resulted in colds developing in these patients5. Simultaneously, another group was able to grow a 
virus that seemed to have “unusual properties” from samples obtained from medical students 
who also had colds6. This virus was named 229E. In the late 1960’s, Tyrell et al. began to work 
with not only human strains but also many animal viruses, which included 229E, Mouse 
Hepatitis Virus (MHV) and a gastroenteritis virus of swine, which would later be named PEDV5. 
Looking at the various strains under the electron microscope he noted that the particles were 
pleomorphic, membrane coated and covered with club-like projections on the surface. This new 
family of viruses, having a crown-like appearance, was officially named the Coronaviridae. As 
further studies began to look more in depth at the pathology and the epidemiology of 
coronaviruses, the number of identified animal CoVs grew at a rapid rate. Researchers were able 
to isolate CoVs that caused disease in many animal species, which include but are not limited to 
cats, dogs, rabbits, mice, rats, chickens, turkeys and most importantly bats7. Fast forward to 
current day, using sequence analysis, researchers have been able to identify four subfamilies of 
CoVs that include, alpha, beta, gamma and delta CoVs (Figure 1). Currently, there are only six 
CoVs that infect humans: alpha Co’s 229E, NL63 and beta CoV’s OC34, HKU1, SARS-CoV, 
and MERS-CoV (Figure 1). Of the viruses that infect humans, the latter two listed are the most 
pathogenic.  
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Figure 1. Phylogenic Tree of Coronavirus Family. Above depicts numerous strains of viruses 
that have currently been identified to belong to the four CoV subtypes: alpha, beta, gamma, and 
delta. Highlighted in the red boxes are the current strains that have been identified to infect 
humans. The phylogenic tree was comprised of partial nucleotide sequences of RNA-dependent 
polymerase. Modified from Chan et al.8   
 
CoV Structure and Replication. 
CoVs are spherical, enveloped viruses, which house a single-stranded, positive sense 
RNA genome. These enveloped virions are studded with spike proteins on the surface. The 
surface of CoVs are made up of membrane proteins and a host derived envelope. Some strains 
also contain a hemagglutinin-esterase protein that is needed for releasing the viral genome during 
infection. Inside this enveloped virion is the positive strand RNA genome covered in 
nucleocapsid protein (Figure 2). 
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Figure 2. Schematic diagram of the typical virion structure for a Coronavirus. CoVs 
produce a spherical shaped virion that contains a single stranded RNA genome that is encased in 
nucleocapsid protein. (S) Spike protein is a transmembrane protein that forms the spike-like 
projections that interacts with host’s surface receptor to allow endocytosis to occur. (M) 
Membrane houses the viral RNA. (E) Envelope protein that is derived from the host and also 
serves as a barrier for protection. (R) Viral RNA genome that encodes all of the structural and 
non-structural proteins used during the viral lifecycle to produce and infectious virion. (N) 
Nucleocapsid protein covers the viral genome and protects the RNA when injected into the host 
cell cytoplasm9. 
 
Upon viral infection, the virus enters a cell through receptor-mediated endocytosis or 
fuses directly at the cell membrane for entry into a host cell1. The genomic RNA, once released 
into the cytoplasm, is translated into two large polyproteins termed ORF1a/b, which encode the 
replication machinery needed for viral replication and are processed by the virus-encoded 
autocatalytic non-structural proteins. The genome also encodes structural and accessory proteins 
at the 3’ end10,11. Although all of the functions of the non-structural proteins (NSPs) that CoV’s 
genome encode have yet to be identified, it is known that some of the NSPs will interact with the 
host endoplasmic reticulum (ER) allowing the formation of double-membrane vesicles (DMVs). 
Membrane	
protein	(M) 
Spike	Trimer	protein	
(S)
RNA	genome	(R)	encased	in	nucleocapsid	
protein	(N)
Envelope	protein	
(E)	
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Inside these DMVs, other NSPs combine to make replication complexes and allow for genomic 
replication. The structural proteins, viral genome, nucleocapsid and viral envelope are assembled 
at the ER-Golgi intermediate compartment. Once assembly of the new virion is complete, the 
newly infectious viral particle is released from the cell 12,13 (Figure 3). 
 
Figure 3. Coronavirus Replication Cycle. Depicted above is the general CoV replication cycle. 
Replication initiates with receptor mediated endocytosis, or fusing at the cell membrane. Upon 
entry into the cell the viral genome is released into the cytoplasm where the positive strand 
genome is translated to make two large polyproteins that encode the viral replicase machinery. 
Following the production of the replicase machinery, viral transcription occurs in double 
membrane vesicles derived from the ER-Golgi complex. Virions are packaged and matured 
within the double membrane vesicles, as they travel towards the host membrane. These vesicles 
that contain the infectious virion is then released from the cell.  Modified from Zhu et al.14 
 
Coronavirus Genome. 
As members of the Nidovirales order, CoVs have a unique coding strategy: a majority of 
viral RNA is translated into two large polyproteins and the remainder of the viral genome is 
Fusion
CoV Receptor
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transcribed into a nested set of subgenomic mRNAs10,13.  The two polyproteins encode 16 non-
structural proteins that make up the viral replicase-transciptase complex15. Containing a large 
viral genome is very unique, and this is able to be achieved because CoVs genome encodes an 
exoribonuclease that functions as a proofreading mechanism and allows for the maintenance of 
the large viral genome without accumulating deleterious mutations16,17. This large viral genome 
that is characteristic of CoVs is actually highly conserved amongst the CoV’s subtypes (Figure 
4). The conservation of gene order and function has been key in studying emerging viruses. This 
highly conserved gene order and function is the key component in many successful CoV 
infections. It can be appreciated that it is the accessory proteins and mutations in the viral spike 
that aid the CoV’s ability to have a large range of host tropism18. However, it is the function of 
the  polyproteins of the viral genome that aids in the efficient replication of these viruses19. 
These viruses have a conserved gene order and function because they arose from a common 
ancestor: the bat. 
 
Figure 4. CoVs contain a conserved genome organization. Depicted above are two CoV 
genomes from two different strains of the virus. MHV is able to infect mice and SARS infects 
humans, yet they have a very similar genome organization. These two different viruses have very 
different host tropism but all retain similar replication machinery needed for successful viral 
infection. Although the other strains of CoVs are not depicted, these are a representation of the 
MHV-A59
SARS-COV
Non-Structural	Proteins	
(replication	machinery)
Structural	and	Accessory	Proteins
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conserved viral genomes organization present in the non-structural protein portion of their 
genome. Modified from Belouzard et al.8 
 
Bats: Coronavirus’s Natural Reservoir. 
Although CoVs are dangerous due to their pathogenicity, another very important factor 
that should be considered is their high rate of zoonotic transmission. A study was done to 
determine which animal species harbored the most novel viral sequences and bats were identified 
as the number one candidate20. Bats are an advantageous host for viruses for a number of 
reasons. First, these mammals have the ability to occupy diverse niches, which allows these 
animals to interact with large colonies of other bats and animals18,21. The interactions with other 
bats allow for the transmission of different CoV’s to co-infect a single bat, resulting in the 
opportunity for multiple quasi species to maintain a low-level of infection and recombine, 
resulting in populations of viruses that can infect a broad range of hosts22. Secondly, as humans 
continue to colonize more of the earth’s natural landscape, we begin to force bats to have more 
interactions with species (i.e. humans and other animals) they may not commonly come into 
contact with. These interactions aid the transmission of CoVs from bats to other mammals, in 
which they would not readily infect. A prime example of this gain of host tropism is the 
emergence of SARS CoV and MERS CoV22. Although these CoVs originated in bats, due to 
mutations and interactions these viruses were able to gain tropism to allow them to infect an 
intermediate host (civet cats and camels) and ultimately gain human tropism18,23,24 (Figure 5). 
Aside from these diverse niches, it also has to be taken into consideration that these animals are 
migratory in nature. This migratory behavior is very advantageous for an emerging virus, giving 
the virus the opportunity to have a broad geographical area in which these viruses potentially can 
disseminate.   
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Figure 5. CoVs have the ability to gain human tropism. SARS and MERS to date have been 
the most pathogenic CoVs resulting in hundreds of deaths combined. These viruses emerged into 
humans by gaining mutations that allowed the viruses to have cross species transmission and 
ultimately, use these secondary reservoirs as zoonotic modes of transmission. Depicted above are 
the routes that SARS and MERS took to become introduced into the human population. Image 
modified from Wit et al.11 
 
It has yet to be fully elucidated as to why bats have the ability to harbor more than one 
species of CoVs and result in an asymptomatic infection24. There are several proposed 
hypotheses as to why multiple CoV infections seem to have no deleterious effects on the bats 
they infect.  First, it is has been proposed that bats are able to produce high levels of reactive 
CoV
CoV
2002
>30	years	ago
MERS-CoV
SARS-CoV
Cross-species	
transmission
Zoonotic	
transmission
Rare
Continuous	
Community	 Contact
Hospital	Patients
+
Health	care	personnel
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oxygen species (ROS) which controls genes that limit oxidative stress, resulting in reduced viral 
replication and pathogenesis25,26. Also, studies have shown that bats harbor a modified innate 
immune response that potentially also contributes to the diverse population of CoVs that these 
mammals harbor. Bats also constitutively express interferon subtypes that rationally could limit 
disease while permitting low-level viral infection to happen concurrently27. 
The Emergence of Potentially Pandemic Strains of CoVs. 
In the 21st century, CoVs have proven to be a huge pathogenic threat. In November of 
2002, the first known documented case of a novel CoV infection occurred in  Foshan, China28. 
The patient was admitted with symptoms of fever, dry cough, and shortness of breath. These 
symptoms then resulted in severe respiratory complications, which exhibited symptoms of a deep 
lung infection. Upon initial diagnoses, medical care workers thought the patient had a novel form 
of influenza but upon testing the results were negative. By February of 2003 more than 300 
individuals had been admitted to the hospital for the same symptoms with and unknown cause11. 
In March of 2003 the World Health Organization (WHO) established a network of laboratories 
that were able to identify the causative agent as the emergence of SARS-CoV. By the end of 
2003, the SARS emergence resulted in 774 deaths4. The SARS CoV outbreak was contained by 
isolation of infected patients and their contacts.  
A decade later in June of 2012 another novel CoV, MERS, was isolated from the sputum 
of an infected patient in Saudi Arabia29. MERS-CoV continued to emerge and spread outside of 
the Arabian Peninsula due to infected people traveling out of the country. Since then, there has 
been a slow spread of infection throughout the Middle East. As of April of 2016, there have been 
1,728 confirmed cases of MERS, which resulted in 624 deaths in 27 countries3. Thus, the need to 
find a vaccine has become of the upmost importance. 
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Studying CoVs: Animal Model.  
In order to study CoVs in a laboratory safe environment, researchers use the model 
animal CoV Mouse Hepatitis Virus (MHV).  MHV is a beta CoV that causes illness in mice with 
a high mortality rate. Although the pathogenic characteristics differ from that of SARS and 
MERS, the high mortality is greater in MHV. MHV has more than 25 isolates, which have may 
different tissue tropism, but the incidence of enteric infection of MHV strains is most 
common30,31. Some strains of MHV can cause progressive demyelinating encephalitis in mice, 
which has also been used as an animal model for multiple sclerosis32. This CoV is readily found 
in laboratory settings and can be transmitted via fecal-oral, direct contact, aerosols and fomite 
transmission. Although vertical transmission has been observed in experimental infections, this 
does not occur in spontaneous infections33,34. In immune competent mice, MHV is very 
subclinical in its pathology30,34. Expression of disease phenotype is directly dependent upon the 
virus strain and host factors, which include age, genotype, and immune function34. Upon 
studying the histopathology of infected mice, the intestinal tracts exhibit syncytia in the mucosal 
epithelial tissue34. MHV aside from being a murine tropic virus is also a great model because it 
contains the highly conserved gene order and function that is characteristic of CoVs19. MHV is 
the most highly studied CoV in-vivo and in-vitro at the molecular level. The majority of research 
projects that use MHV as a model, focus on viral pathogenesis and understanding of how CoVs 
interact and alter host immune functions. With the development of a reverse genetics system for 
MHV, the isolation and study of individual mutations in certain viral genes can be assessed. I can 
then identify mutations that specifically effect virus-host interactions resulting in a better 
outcome for the host35. 
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Identifying Attenuating Mutations. 
 Different methods are essential for identifying critical mutations that attenuate the virus. 
One such method of identifying deleterious mutations, is to induce mutations in the virus and 
screen for TS mutations. TS mutations are unique because under permissive conditions the 
mutations are able to confer a normal functioning gene product. In contrast, under non-
permissive conditions the mutation will result in a gene product that displays a mutated 
phenotype. Identifying TS mutations can tell you many things about the pathogen. This method 
has been used primarily as a genetic tool. In 1965, Edgar et al. used TS phenotyping to identify 
the number of genes in a novel strain of bacteriophage T4D36. By using chemical mutagenesis 
and screening the mutant progeny for growth under different temperature conditions, this group 
was able to identify 37 individual genes the phage contained36. These mutations classically aid in 
the identification of essential genes in an unknown pathogen’s genome.  However, with the 
advancement in technology these TS mutations can now be induced and identified by sequencing 
down to the exact residue conferring the TS phenotype. 
  Complementation analysis can be used to verify that the mutant progeny observed from 
chemically inducing TS mutations are unique. Complementation analysis is a special and critical 
analysis that has been used throughout research in lieu of sequencing to identify not only the 
unique mutants but to also aid in predicting where in the genome these mutations may be 
located. Edgar et al., after identifying the chemically induced strains of T4D bacteriophage were 
TS, used complementation to verify they were unique mutants and to begin to map where these 
mutations were located36,37. Complementation analysis involves the co-infection of two mutated 
phage that are grown under non-permissive conditions and assessed for successful phage 
production. Individually the phage are unable to grow at non-permissive conditions38. Thus, if 
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the two strains of phage contained the same mutations, they would not be able to complement or 
“over-come” the attenuating mutations because they are located in the same region. However, if 
the phage contains different mutations these mutant phage would be able to propagate infectious 
progeny because the phage were able to complement each other due to the mutations being 
located in different locations thus allowing the phage to “over-come” the attenuating mutations 
each phage contains individually. 
Phenotyping CoVs: MHV. 
In order to design a method to develop a vaccine strain that contains mutations that may 
help to protect against current and future strains emergence, we first must identify areas of 
attenuation in conserved regions of the viral genome. As I previously stated, the one common 
factor that aids in CoVs success in infection is also a chink in the armor, the highly conserved  
gene order and functions amongst the CoV family. By using different techniques, one may be 
able to identify key residues that attenuate the virus in an essential gene. For example, currently 
in vaccine development many attenuated strains contain a mutated structure/surface protein. 
Although this is typically the most common method, it also has to be taken into account that 
surface proteins tend to undergo a high rate of mutation to evade the immune response and are 
typically very tolerable of mutations. In contrast, finding a mutation in a conserved region that 
does not tolerate mutations presents the opportunity to potentially identify sites for attenuation 
that are common amongst current and potentially emerging CoV strains.  
TS mutants of animal viruses have been very useful for studying many critical functions 
of  individual viral genes 36,39,40. These studies have allowed researchers to understand 
pathogenic, biochemical and pathological characteristics of these viruses with a goal to find an 
attenuating mutation that can be used to produce a vaccine strain. In 1983, Koolen et al. sought 
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to understand the viral genome of MHV39. Prior to his studies, not much was known about 
coronaviruses nor its genome, but by using this animal model, they sought to identify different 
viral genes and their roles in the viral life cycle39. In order to decipher the contents of the viral 
genome, a chemical mutagenesis was performed on over 1,284 viral clones39. To verify that 
these mutants were TS, the viruses were allowed to grow under three conditions (33, 37 or 
40oC)39. If the mutant viruses showed a defect or reduction in titer at 40oC, these viruses were 
deemed TS39. Of these clones, they were able to identify 20 TS mutants, that were classified into 
two categories, RNA + or RNA -. If the virus was RNA-, the virus was unable to synthesize viral 
RNA at non-permissive temperatures (40oC)39. RNA+ TS mutants were documented to still grow 
at all three temperatures, but were shown to have a reduction in titer as the temperature 
increased.  
In 1990, Baric et al. sought to understand the function of the MHV polymerase genes to 
better understand how MHV transcription occurs 38. Taking a similar approach as Koolen ten 
years earlier, chemical mutagenesis was performed to identify areas in the viral genome that 
tolerated mutations under permissive conditions38. Several chemical mutagenesis experiments 
were performed to induce mutations throughout the genome. 26 mutant viruses containing 
genetic mutations were isolated. These mutants were assessed for phenotypes that differ to that 
of Wild Type virus. All 26 mutant strains were reported to have reduced viral titers and defects 
in RNA synthesis during temperature shift experiments 38. Using complementation analysis, this 
group determined the number of genes or genetic functions that were altered by the chemical 
mutagenesis. The Baric Lab identified six complementation groups, each representing a 
hypothesized area of mutation in the viral genome38. The temperature-dependent phenotype 
paired with the reduction in viral titer led the Baric Lab to hypothesize that the mutations were in 
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the viral replication machinery. Of these mutants that were derived, LA16 and NC2 stood out as 
potential candidates that should receive further studies. LA16 and NC2 are both hypothesized to 
have mutations in the replication machinery, thus giving them their documented TS phenotype.  
No further analysis was performed to identify the location of these mutations. By identifying the 
locations of these mutations, potentially I may potenitally be able to identify a novel target of 
attenuation that is conserved amongst many strains of CoVs. This information will be important 
in the development of a vaccine strain for protection from current and future stains of CoVs. 
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Aims and Hypothesis 
 
Over the past 15 years, CoVs have exhibited both rapid and highly pathogenic 
emergences into the human population, eluding to the potential to cause a world-wide pandemic. 
Prime examples of this emergence were observed by the emergence of SARS-CoV in 20034, 
which resulted in 774 deaths, followed by the emergence of MERS-CoV, in 2012, which resulted 
in 624 deaths thus far3. These unanticipated zoonotic jumps into the human population highlight 
the need to produce common methods or identify conserved targets of attenuation that can be 
used for generating vaccines against diverse CoV species. Although CoVs are infamous for 
having diversity in host tropism, one common factor of CoVs is a highly-conserved genome 
order and function. It is important to identify attenuation mutations in conserved genes or 
residues because it allows for the development of vaccine strains or direct-acting antivirals that 
can act on current and future emerging CoVs. The goal of this study is to identify conserved 
targets of attenuation, with the intention of identifying a strategy to make vaccines that can 
protect against the current circulating strains but also for future coronavirus outbreaks.  For my 
thesis, I propose to identify the TS phenotype of two previously derived TS mutants of MHV, 
NC2 and LA16, followed by deep genomic sequencing to identify the location of these mutations 
within the viral genome. I hypothesize that LA16 and NC2 harbor mutations in the viral 
polymerase machinery conferring their TS phenotype. In AIM 1, I will characterize LA16 and 
NC2 by performing plaque assays under three different conditions to verify the TS phenotype40. 
In AIM 2, I will identify the mutations present in the RNA genome of NC2 and LA16 by 
genomic deep sequencing. By identifying the mutations in the viral genome, I can further 
hypothesize whether individual or collective mutations confer a TS phenotype.
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Significance 
 
By conducting this study, we will gain information on novel mutations that lead to virus 
attenuation. TS phenotyping has become a key method in identifying novel gene functions of 
many unknown pathogens 36,37. By identifying the mutations that result in a TS phenotype we 
can begin to investigate how mutations in certain viral genes affect virus-host interactions 
resulting in a better outcome for the host. In this proposal, we will combine classic genetic 
phenotyping techniques with current genomic sequencing to identify novel attenuating 
mutations. By confirming the TS phenotype of these mutant strains of a model CoV MHV, we 
will be able to confirm the accuracy and reproducibility that chemical mutagenesis can offer as 
well as establish the stability of the progeny that come from this technique. With the 
advancement of sequencing we can pin-point mutations that are located in highly conserved 
regions of the viral genome with much more accuracy than that of classic complementation and 
gene mapping techniques. Additionally, the information obtained in this study will allow the 
identification of sites in conserved genes that are important for replication. In the future, this 
information could be applied to a variety of CoVs to determine if the mutant viruses could be 
used as vaccines for protection from current and more importantly future strains of CoVs.
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CHAPTER TWO 
MATERIALS AND METHODS 
Virus and Cell lines 
Delayed Brain Tumor (DBT) cells were cultured in minimal essential medium (MEM) 
(Fisher) supplemented with 2.2g NaHCO3, 5% TPB, 2% Penicillin/Streptomycin, 2% L-
Glutamine and 5% heat inactivated Fetal Calf Serum (FCS). Cells were incubated at 37oC in 5% 
CO2 enriched environment. Media, used for plaque assays, is made of 2X MEM supplemented 
with NaHCO3, 5% TPB, 2% Penicillin/Streptomycin, 2% L-Glutamine and 2% FCS.  During 
plaque assays cells were incubated in 5% CO2 at either 33, 37, or 40 oC. Typically, cells were 
passaged 1:3 using trypsin-EDTA to disperse cells from culture plates. Our laboratory stock of 
WT MHV-A59 has been sequenced and propogated in DBT cells35. LA16 and NC2 viral stocks 
were graciously obtained from the Baric Lab41.    
Thawing of Viral Stocks 
To thaw the frozen viral stocks, vials which contained supernatant from virally infected 
cells were flash thawed by incubating in the 37 oC water bath until 90% thawed. During the 
incubation period vials were constantly swirled in bath to ensure even thawing and were placed 
directly on ice once 90% of contents were no longer frozen. Once fully thawed, vials were 
vortexed to equally distribute the virions within supernatant.   
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Performing Plaque Assays 
Cells are plated into a six-well tissue culture dish at a 5 x 105 cells/well confluency. 
These cells are plated in complete MEM supplemented as indicated above. The cells are then 
placed into the 37oC incubator for at least 18 hours prior to infection to allow cells to evenly 
form a monolayer on the bottom of the well. A ten-fold dilution was performed as indicated in 
Figure 6. Dilutions were performed in incomplete MEM on ice. Culturing media was aspirated 
from each well and cells were washed in PBS. 300 µl of viral dilution is applied to the well. 
Cells were incubated at 37 oC, 5% CO2 for one hour, rocking plates gently every 15 minutes. 
During the absorption step, a 1:1 ratio of 2X-MEM and 0.4% Noble Agar was mixed. After the 
one hour incubation period the inoculum was removed and 2 ml of the 2X-MEM and Noble agar 
mix was added to each well. The plates were allowed to sit for ten minutes at room temperature 
(RT) to solidify prior to being moved to the appropriate incubator. Plates were allowed to 
incubate at the determined temperature for 48 hours. After 48 hours, 2 ml of 3.7% 
Formaldehyde-PBS solution was added to each well and incubated for 30 minutes at RT. The 
Formaldehyde-PBS solution/agar solution was removed and plates were washed with tap water. 
1 ml of 0.1% Crystal Violet solution is added and allowed to incubate at RT for 15 mins on a 
rocker. Crystal violet was removed and plates rinsed and allowed to dry overnight. Plaques were 
then counted by hand.  
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Figure 6. Diluting Viral stock for plaque assay. In order to accurately determine viral titer 
serial dilutions are performed and applied to DBT cells in sequential order. Viral titer is back 
calculated based on the number of plaques produced after incubation. One plaque represents the 
identification of a successful viral infection indicated by the appearance of plaques.  Modified 
from Dulbecco et al42,43.     
 
 
Calculating Viral Titer 
 In order to calculate viral titer, individual plaques were hand counted and documented. 
Using the following equation, the viral titer was able to be calculated using the amount of 
inoculum added and the number of plaques produced (Equation 1). By multiplying the number of 
plaques by the dilution they were formed by 1000ul divided by the amount of inoculum will 
result in the viral titer. 
 
 
(Eq 1)   
(#	𝑷𝒍𝒂𝒒𝒖𝒆𝒔)	𝒙	 𝟏𝒅𝒊𝒍𝒖𝒕𝒊𝒐𝒏𝒙	(𝟏𝟎𝟎𝟎𝒖𝒍/𝒎𝒍)𝒗𝒐𝒍𝒖𝒎𝒆	𝒑𝒍𝒂𝒕𝒆𝒅	(𝒎𝒍) =	pfu/ml = Viral Titer 
 
 
 
 
 
DBT	Cells
Incomplete	MEM
MHV	Stock
48	hrs
0.3ml 0.3ml 0.3ml
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Imaging and Quantifying Plaques 
Plaques were photographed after fixation. Images were taken after the indicated 
incubation time and temperatures using a consistent magnification with a Zeiss Stemi 2000-C 
dissecting microscope. Photos were then uploaded to Microsoft Photoshop. Once uploaded the 
lasso tool was used to outline the clear boarder of the plaques. Once the plaque was outlined the 
image tab was selected and from the drop-down menu the analysis option was highlighted and 
the record measurement tab was selected. Upon selection of this option, the number of pixels are 
calculated within the outlined plaque. These represent the area in which the plaque occupies and 
is used as the area of the plaque. Five individual plaques were assessed at random for each 
indicated temperature for each strain.  
Genomic Deep Sequencing and Sequencing Analysis 
 In order to obtain viral genomic sequences, DBT cells were infected with LA16 or NC2. 
After 48 hours of incubation in 33oC, the cellular supernatant is harvested. Supernatant is 
centrifuged at 5,000g for ten minutes. The viral supernatant was then added to naïve DBT cells 
to assess the presence of infectious virus production, verified by plaque formation. 1 ml of the 
cleared viral supernatant was shipped to Kansas State University’s Integrated Genomics Facility 
in which deep genomic sequencing was performed44. The consensus nucleotide sequence was 
provided in a word processor format which was entered into a genomic sequence file in Clone 
Manager. Once imputed into Clone Manager, the nucleotide sequence alignment function was 
applied to compare the sequences of LA16, NC2 and WT MHV (MHV full genome geneID 
reference accession number: NC_001846). The Blossum 65 Alignment function within Clone 
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Manager was applied to compare and identify amino acid differences between LA16, NC2 and 
WT sequences. 
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CHAPTER THREE 
RESULTS 
Validation of Temperature-sensitive Phenotype of NC2 and LA16 
To determine if the viral stocks of LA16 and NC2 obtained from the Baric lab were TS, 
plaque assays were performed at 33, 37 and 40oC. DBT cells were infected with serial dilutions 
of the viral stock. The cells were incubated at different temperatures for 48 hours prior to 
fixation (Figure 7). Temperature sensitivity was assessed by viral titer and plaque morphology at 
the different temperatures. As a positive control a WT MHV infection was performed as well. It 
has been well documented that WT MHV, under all three conditions, is able to maintain the 
same viral titer, but exhibits an increase in plaque size35,40,41,45. The increase in plaque size is due 
to the increase in metabolic rate of the cells under these conditions, resulting in an increase in 
viral replication, i.e. plaque size. WT MHV at 33, 37 and 40oC exhibit normal plaque 
morphology with a slight increase in plaque size as the temperature increases (Figure 7A). 
Although the plaque size increases slightly, it can be appreciated that the number of plaques 
present remains constant. The viral titer was maintained at 6.5 x 106 ± 0.40 pfu/ml (Figure 7B). 
The images of WT MHV at 33, 37 and 40oC were all taken at the 105 dilution in which the 
plaques were able to be visualized individually. 
Assessing Temperature-sensitive Phenotype of LA16 
  When assessing TS mutant LA16 for replication and plaque formation at 33oC, it can be 
noted that the plaques have the same morphology as that of WT,in which  the plaques appear to 
be the same size and shape (Figure 7A). The representative image of LA16 at 330C was taken of
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 a 105 dilution allowing the visualization of individual plaques. The viral titer at 330C was 1.2 x 
107 pfu/ml (Figure 7B). The titer of LA16 at 33oC is similar as the literature documented titer, in 
which Baric et al. documented LA16 to have a 4.9 x 107 pfu/ml titer at 33 oC (Figure 7B)41. This 
conservation of viral titer speaks to the integrity of the samples. When assessing LA16 at 37oC 
the morphology of the plaques can be appreciated at a 1:1000 dilution (Figure 7A). At this 
temperature, the plaques have a heterogeneous morphology that appear to range from small to 
pin-point in size. LA16 has a viral titer of 5.3 x 104 pfu/ml at 37oC (Figure 7B). LA16’s titer is v 
similar to the documented titer of  2.7 x 104 pfu/ml when shifted to 37 oC41. A reduction in titer 
was observed at 37oC compared to the titer at 33oC.  Upon assessing the titer of LA16 at 40oC, I 
was unable to be detect any plaques using our assay, which has the sensitivity to detect 100 
pfu/ml. This lack of detection at 40oC as well as the reduction in viral titer further validates that 
LA16 has retained its TS phenotype as documented in the literature. 
Assessing TS Phenotype of NC2 
In order to validate that NC2 is TS, as documented in the literature, a plaque assay was 
performed at different temperatures in which the morphology and viral titer were assessed. At 
33oC, NC2 plaque morphology is very similar to that of WT at 33oC. These plaques appeared 
rather round in shape and the representative image was taken at 105 dilution, which was the same 
as LA16 and WT (Figure 7A). When assessing the viral titer of NC2 at 33oC, the titer was 
calculated at 1.04 x 107 pfu/ml (Figure 7B). This titer correlates with the viral titer documented 
in the literature as 5.6 x 107 pfu/ml41. Upon incubating NC2 at 37oC, the plaques maintained their 
size and similar titer, resembling that of WT. The representative image of NC2 at 37oC (Figure 
7A) was taken at a 105 dilution. Although there was a ten-fold decrease in the viral titer, the 
morphology of the plaques remained constant. At 37oC NC2 has a titer of 106 pfu/ml. When NC2 
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was incubated at 40oC, the plaques uniformly changed to a pin-point morphology (Figure 7A). 
Upon checking the titer of NC2 at 40oC, the titer was 5.3 x 104 pfu/ml (Figure 7B). This titer was 
slightly higher than the documented titer which was 4.0 x 103 pfu/ml41. The reduction of viral 
titer and change in plaque morphology, upon the increase of incubation temperature validates the 
integrity of NC2 as TS, as documented in the literature.      
 
	  
Figure 7. Comparison of Murine Coronavirus strains LA16 and NC2 to asses for 
Temperature-sensitive defects in replication. (A) Visual representations of plaques that were 
generated by WT, LA16, and NC2 after incubation in the indicated temperatures. DBT cells 
were infected with WT, NC2 or LA16 incubated at the indicated temperature and stained 48 
hours post infection. These images were representative data from two independent experiments. 
(B) Summary of the characteristics of WT, LA16, NC2 at different temperatures. Plaque assays 
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were performed using DBT cell and were allowed to incubate at the indicated temperature (33, 
37 or 40oC) for 48 hours. 
 
 
Figure 8. Analysis of WT and LA16 plaque size at different temperatures. Plaque assays 
were performed using DBT cells. DBT cells were infected with LA16 or WT virus, incubated at 
the indicated temperature and fixed 48 post-infection.Five plaques were chosen at random and 
photographed using a fixed camera. These images were analyzed using Adobe Photoshop. 
Photoshop was used to quantify the number of pixels present in the plaque, which is used to 
quantify plaque area. Statistical analysis was performed using Student’s T test. (**p:>0.005. 
***p:>0.0005) 
 
LA16 MHV Exhibits a Reduction in Plaque Size 
 In order to further assess the TS phenotype of LA16, the plaque areas from the plaque 
assay shown in Figure 7A were quantified. DBT cells were inoculated with LA16 and WT 
MHV, and incubated at the indicated temperature for 48 hours. After fixation, images were taken 
using a camera set at a fixed magnification. These images were then assessed in Adobe 
Photoshop. Using the lasso tool in Photoshop the outline of plaque was traced. Once the plaque 
was outlined, Photoshop was able to quantify the amount of pixels within the outlined area 
corresponding to the area that plaque occupies. Five individual plaques were chosen at random 
and assessed at each indicated temperature. In order to ensure the plaques were chosen at 
random, upon fixingthe camera at the correct setting the first five plaques that were unobstructed 
N.D 
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were selected and assessed. Upon comparing WT and LA16 plaque sizes at 33oC, the plaques 
were very similar in size (Figure 8). This also correlates with the morphology shown in Figure 
7A. When comparing the plaque size of WT and LA16 at 37oC, LA16 has a significant decrease 
in plaque size. The reduction in plaque size correlates with the change in morphology (Figure 
7A) and a decrease in viral titer (Figure 7B). Due to the heterogeneous population of plaques 
produced during incubation, the small and entirely cleared plaque population were quantified. 
LA16 failed to produce plaques within the detection limit of the plaque assay when incubated at 
40oC. This data further verify that LA16 is TS. 
NC2 MHV May Contain Mutations That Confer a Reduction in Plaque Size 
 To further validate the TS phenotype of NC2, the plaque area from the plaque assay 
shown in Figure 7A was quantified. DBT cells were inoculated with NC2 and incubated at the 
indicated temperature for 48 hours. WT was incubated at 40oC for 48 hours as a positive control. 
These assays were fixed and images were taken using a fixed camera. These images were then 
assessed in Photoshop. Using the lasso tool in Photoshop the outline of plaque was traced. Once 
the plaque was outlined, Photoshop was able to quantify the area with the outlined area. Five 
individual plaques were chosen at random and assessed at each indicated temperature. The 
average of plaque sizes produced by NC2 are identified at differnet temperatures as shown in 
Figure 9A. When assessing the average of the plaques NC2 produces it can be appreciated that 
the plaque size was maintained from 33 oC to 37 oC. Upon incubating NC2 at 40oC, there was a 
drastic reduction in plaque size (Figure 9A). When comparing the change in plaque size at 40oC, 
NC2 had a significant reduction in plaque size compared to WT (Figure 9B). This also correlates 
with the decrease in titer and change in plaque morphology (Figure 7A). From this preliminary 
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data, I can further validate NC2 is TS and potentially contains different mutations than that of 
LA16.  
 
 
Figure 9. Preliminary Data Quantifying NC2 Plaque Size. (A) Quantification of the average 
plaque size of five individual plaques of NC2. Plaques size was quantified using Adobe 
Photoshop. DBT cells were infected with NC2 or WT virus, and were incubated at the indicated 
temperature and fixed 48 hours post-infection. (B) Quantification of plaque size for NC2 and WT 
MHV at 40oC. Plaques were incubated for 48 hours prior to fixation and quantification. 
Statistical Analysis was performed using Students T-test. (p***0.0005) 
 
Plaque	Size	at	40
o
C 
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Deep Sequencing of LA16 and NC2 Identifies Multiple Mutations in ORF1A 
  Previous data from the Baric lab led to the hypothesis that mutations that conferred the 
TS phenotype of LA16 and NC2 were located in ORF1A41. Both mutants are classified in the 
RNA- group, which has a defect in viral RNA synthesis39,41. The data indicated the RNA 
synthesis defect furthers supports the hypothesis that these mutations may be located in ORF1A 
which contains genes essential for viral replication. Sequencing samples were obtained from the 
supernatant of DBT cells infected with LA16, NC2 or WT at 33oC and incubated for 48 hours 
prior to harvesting. These samples were harvested from the infections incubated at 33oC to avoid 
selecting for mutations that were not originally present in the Baric stock.  Selective pressure 
occurs when growing the viruses at non-permissive conditions. The samples were then cleared of 
cellular debris by centrifugation and sent to a collaborator for genomic deep sequencing. Upon 
receiving the sequencing data, the results were analyzed using Clone Manager function which 
allowed for the alignment of the nucleotide sequence. I also used Blossum 65 to align the three 
genomic sequences at the amino acid level, allowing the identification of nucleotides that result 
in amino acid changes (Figure 10). 
  In analyzing the data, I found that LA16 and NC2 collectively contained 13 nucleotide 
changes in ORF1A. Although there were 13 changes, only eight of these mutations resulted in 
amino acid changes. There were two mutations conserved between both strains, which I 
hypothesize may have been part of the original strain of viruses that these mutants were derived 
from. LA16 contains two unique mutations that resulted in amino acid changes. These mutations 
were located in Nsp3 and Nsp10, genes which have been shown to be important in viral 
replication40,45.  The first unique mutation in LA16 was located in Nsp3, the viral protease. This 
mutation change was in the second position of the codon, which resulted in an “a” nucleotide 
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substituted for a “g”. This substitution resulted in the change of the amino acid from glycine to 
glutamic acid. The second unique mutation was located in Nsp10, whose function has been 
hypothesized to be a regulator of RNA synthesis by controlling polyprotein processing46. This 
mutation resulted in a nucleotide change located in the second nucleotide position for a codon 
that coded for a cysteine. Additionally, this mutation resulted in an amino acid that was changed 
from a cysteine to a tryptophan.  
  In analyzing the data from NC2, it was noted  there were four unique mutations that 
resulted in amino acid changes. These mutations were located in Nsp3, Nsp4 and Nsp5. Of these 
four unique mutations, three were conservative, resulting in a substitution of amino acids that 
have conserved properties. However, there was one unique mutation that was located in Nsp3. 
This mutation occurred in the first position of the codon, resulting in an amino acid change from 
Lysine to Glutamic Acid. The sequencing data reveal that LA16 and N2 both contain mutations 
in ORF1A, may be responsible for the TS phenotype observed in each strain.  
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Figure 10. Genomic Sequence Alignment of WT, LA16 and NC2 of ORF1A. Using the 
Blossum 65 (clone manager) function the amino acid sequence was determined and was used to 
identify amino acid changes resulting from a change in the nucleotide sequence. (Black) The WT 
reference strain nucleotide sequence. (Green)The corresponding amino acids associated with the 
WT nucleotide sequence directly beneath the WT codon. (Highlighted nucleotide codon) 
Represents the codon in WT that was mutated in LA16 or NC2. (Red)Represents the mutated 
nucleotide within the highlighted codon that was changed. (Blue) Indicates a nucleotide mutation 
that resulted in a silent mutation. (Purple) Nucleotide change that resulted in an amino acid 
change. (Purple letter) Amino acid change. The sequence starts at the first methionine in 
ORF1A. This corresponds to nucleotide 210 in the full genomic sequence. 
 
WT   1  atg gca aag atg ggc aaa tac ggt ctc ggc ttc aaa tgg gcc cca gaa ttt cca tgg atg ctt ccg aac 
          m   a   k   m   g   k   y   g   l   g   f   k   w   a   p   e   f   p   w   m   l   p   n 
 
    70  gca tcg gag aag ttg ggt aac cct gag agg tca gag gag gat ggg ttt tgc ccc tct gct gcg caa gaa 
          a   s   e   k   l   g   n   p   e   r   s   e   e   d   g   f   c   p   s   a   a   q   e 
 
   139  ccg aaa gtt aaa gga aaa act ttg gtt aat cac gtg agg gtg aat tgt agc cgg ctt cca gct ttg gaa 
          p   k   v   k   g   k   t   l   v   n   h   v   r   v   n   c   s   r   l   p   a   l   e 
 
   208  tgc tgt gtt cag tct gcc ata atc cgt gat att ttt gta gat gag gat ccc cag aag gtg gag gcc tca 
          c   c   v   q   s   a   i   i   r   d   i   f   v   d   e   d   p   q   k   v   e   a   s 
 
   277  act atg atg gca ttg cag ttc ggt agt gcc gtc ttg gtt aag cca tcc aag cgc ttg tct att cag gca 
          t   m   m   a   l   q   f   g   s   a   v   l   v   k   p   s   k   r   l   s   i   q   a 
 
   346  tgg act aat ttg ggt gtg ctt ccc aaa aca gct gcc atg ggg ttg ttc aag cgc gtc tgc ctg tgt aac 
          w   t   n   l   g   v   l   p   k   t   a   a   m   g   l   f   k   r   v   c   l   c   n 
 
   415  acc agg gag tgc tct tgt gac gcc cac gtg gcc ttt cac ctt ttt acg gtc caa ccc gat ggt gta tgc 
          t   r   e   c   s   c   d   a   h   v   a   f   h   l   f   t   v   q   p   d   g   v   c 
 
   484  ctg ggt aat ggc cgt ttt ata ggc tgg ttc gtt cca gtc aca gcc ata ccg gag tat gcg aag cag tgg 
          l   g   n   g   r   f   i   g   w   f   v   p   v   t   a   i   p   e   y   a   k   q   w 
 
   553  ttg caa ccc tgg tcc atc ctt ctt cgt aag ggt ggt aac aaa ggg tct gtg aca tcc ggc cac ttc cgc 
          l   q   p   w   s   i   l   l   r   k   g   g   n   k   g   s   v   t   s   g   h   f   r 
 
   622  cgc gct gtt acc atg cct gtg tat gac ttt aat gta gag gat gct tgt gag gag gtt cat ctt aac ccg 
          r   a   v   t   m   p   v   y   d   f   n   v   e   d   a   c   e   e   v   h   l   n   p 
 
   691  aag ggt aag tac tcc tgc aag gcg tat gct ctt ctt aag ggc tat cgc ggt gtt aag ccc atc ctg ttt 
          k   g   k   y   s   c   k   a   y   a   l   l   k   g   y   r   g   v   k   p   i   l   f 
 
   760  gtg gac cag tat ggt tgc gac tat act gga tgt ctc gcc aag ggt ctt gag gac tat ggc gat ctc acc 
          v   d   q   y   g   c   d   y   t   g   c   l   a   k   g   l   e   d   y   g   d   l   t 
 
   829  ttg agt gag atg aag gag ttg ttc cct gtg tgg cgt gac tcc ttg gat agt gaa gtc ctt gtg gct tgg 
          l   s   e   m   k   e   l   f   p   v   w   r   d   s   l   d   s   e   v   l   v   a   w 
 
   898  cac gtt gat cga gat cct cgg gct gct atg cgt ctg cag act ctt gct act gta cgt tgc att gat tat 
          h   v   d   r   d   p   r   a   a   m   r   l   q   t   l   a   t   v   r   c   i   d   y 
 
   967  gtg ggc caa ccg acc gag gat gtg gtg gat gga gat gtg gta gtg cgt gag cct gct cat ctt ctc gca 
          v   g   q   p   t   e   d   v   v   d   g   d   v   v   v   r   e   p   a   h   l   l   a 
 
  1036  gcc aat gcc att gtt aaa aga ctc ccc cgt ttg gtg gag act atg ctg tat acg gat tcg tcc gtt aca 
          a   n   a   i   v   k   r   l   p   r   l   v   e   t   m   l   y   t   d   s   s   v   t 
 
  1105  gaa ttc tgt tat aaa acc aag ctg tgt gaa tgc ggt ttt atc acg cag ttt ggc tat gtg gat tgt tgt 
          e   f   c   y   k   t   k   l   c   e   c   g   f   i   t   q   f   g   y   v   d   c   c 
 
  1174  ggt gac acc tgc gat ttt cgt ggg tgg gtt gcc ggc aat atg atg gat ggc ttt cca tgt cca ggg tgt 
          g   d   t   c   d   f   r   g   w   v   a   g   n   m   m   d   g   f   p   c   p   g   c 
 
  1243  acc aaa aat tat atg ccc tgg gaa ttg gag gcc cag tca tca ggt gtt ata cca gaa gga ggt gtt cta 
          t   k   n   y   m   p   w   e   l   e   a   q   s   s   g   v   i   p   e   g   g   v   l 
 
  1312  ttc act cag agc act gat aca gtg aat cgt gag tcc ttt aag ctc tac ggt cat gct gtt gtg cct ttt 
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          f   t   q   s   t   d   t   v   n   r   e   s   f   k   l   y   g   h   a   v   v   p   f 
 
  1381  ggt tct gct gtg tat tgg agc cct tgc cca ggt atg tgg ctt cca gta att tgg tct tct gtt aag tca 
          g   s   a   v   y   w   s   p   c   p   g   m   w   l   p   v   i   w   s   s   v   k   s 
 
  1450  tac tct ggt ttg act tat aca gga gta gtt ggt tgt aag gca att gtt caa gag aca gac gct ata tgt 
          y   s   g   l   t   y   t   g   v   v   g   c   k   a   i   v   q   e   t   d   a   i   c 
 
  1519  cgt tct ctg tat atg gat tat gtc cag cac aag tgt ggc aat ctc gag cag aga gct atc ctt gga ttg 
          r   s   l   y   m   d   y   v   q   h   k   c   g   n   l   e   q   r   a   i   l   g   l 
 
  1588  gac gat gtc tat cat aga cag ttg ctt gtg aat agg ggt gac tat agt ctc ctc ctt gag aat gtg gat 
          d   d   v   y   h   r   q   l   l   v   n   r   g   d   y   s   l   l   l   e   n   v   d 
 
  1657  ttg ttt gtt aag cgg cgc gct gaa ttt gct tgc aaa ttc gcc acc tgt gga gat ggt ctt gta ccc ctc 
          l   f   v   k   r   r   a   e   f   a   c   k   f   a   t   c   g   d   g   l   v   p   l 
 
  1726  cta cta gat ggt tta gtg ccc cgc agt tat tat ttg att aag agt ggt caa gct ttc acc tct atg atg 
          l   l   d   g   l   v   p   r   s   y   y   l   i   k   s   g   q   a   f   t   s   m   m 
 
  1795  gtt aat ttt agc cat gag gtg act gac atg tgt atg gac atg gct tta ttg ttc atg cat gat gtt aaa 
          v   n   f   s   h   e   v   t   d   m   c   m   d   m   a   l   l   f   m   h   d   v   k 
 
  1864  gtg gcc act aag tat gtt aag aag gtt act ggc aaa ctg gcc gtg cgc ttt aaa gcg ttg ggt gta gcc 
          v   a   t   k   y   v   k   k   v   t   g   k   l   a   v   r   f   k   a   l   g   v   a 
 
  1933  gtt gtc aga aaa att act gaa tgg ttt gat tta gcc gtg gac att gct gct agt gcc gct gga tgg ctt 
          v   v   r   k   i   t   e   w   f   d   l   a   v   d   i   a   a   s   a   a   g   w   l 
 
  2002  tgc tac cag ctg gta aat ggc tta ttt gca gtg gcc aat ggt gtt ata acc ttt gta cag gag gtg cct 
          c   y   q   l   v   n   g   l   f   a   v   a   n   g   v   i   t   f   v   q   e   v   p 
 
  2071  gag ctt gtc aag aat ttt gtt gac aag ttc aag gca ttt ttc aag gtt ttg atc gac tct atg tcg gtt 
          e   l   v   k   n   f   v   d   k   f   k   a   f   f   k   v   l   i   d   s   m   s   v 
 
  2140  tct atc ttg tct gga ctt act gtt gtc aag act gcc tca aat agg gtg tgt ctt gct ggc agt aag gtt 
          s   i   l   s   g   l   t   v   v   k   t   a   s   n   r   v   c   l   a   g   s   k   v 
 
  2209  tat gaa gtt gtg cag aaa tct ttg tct gca tat gtt atg cct gtg ggt tgc agt gaa gcc act tgt ttg 
          y   e   v   v   q   k   s   l   s   a   y   v   m   p   v   g   c   s   e   a   t   c   l  
LA16                                                                        ..c 
NC2                                                                         ..c 
  2278  gtg ggt gag att gaa cct gca gtt ttt gaa gat gat gtt gtt gat gtg gtt aaa gcc cca tta aca tat 
          v   g   e   i   e   p   a   v   f   e   d   d   v   v   d   v   v   k   a   p   l   t   y 
 
  2347  caa ggc tgt tgt aag cca ccc act tct ttc gag aag att tgt att gtg gat aaa ttg tat atg gcc aag 
          q   g   c   c   k   p   p   t   s   f   e   k   i   c   i   v   d   k   l   y   m   a   k 
 
  2416  tgt ggt gat caa ttt tac cct gtg gtt gtt gat aac gac act gtt ggc gtg tta gat cag tgc tgg agg 
          c   g   d   q   f   y   p   v   v   v   d   n   d   t   v   g   v   l   d   q   c   w   r 
 
  2485  ttt ccc tgt gcg ggc aag aaa gtc gag ttt aac gac aag ccc aaa gtc agg aag ata ccc tcc acc cgt 
          f   p   c   a   g   k   k   v   e   f   n   d   k   p   k   v   r   k   i   p   s   t   r 
 
  2554  aag att aag atc acc ttc gca ctg gat gcg acc ttt gat agt gtt ctt tcg aag gcg tgt tca gag ttt 
          k   i   k   i   t   f   a   l   d   a   t   f   d   s   v   l   s   k   a   c   s   e   f 
 
  2623  gaa gtt gat aaa gat gtt aca ttg gat gag ctg ctt gat gtt gtg ctt gac gca gtt gag agt acg ctc 
          e   v   d   k   d   v   t   l   d   e   l   l   d   v   v   l   d   a   v   e   s   t   l 
 
  2692  agc cct tgt aag gag cat gat gtg ata ggc aca aaa gtt tgt gct tta ctt gat agg ttg gca gga gat 
          s   p   c   k   e   h   d   v   i   g   t   k   v   c   a   l   l   d   r   l   a   g   d 
 
  2761  tat gtc tat ctt ttt gat gag gga ggc gat gaa gtg atc gcc ccg agg atg tat tgt tcc ttt tct gct 
          y   v   y   l   f   d   e   g   g   d   e   v   i   a   p   r   m   y   c   s   f   s   a 
 
  2830  cct gat gat gaa gac tgc gtt gca gcg gat gtt gta gat gca gat gaa aac caa gat gat gat gct gaa 
          p   d   d   e   d   c   v   a   a   d   v   v   d   a   d   e   n   q   d   d   d   a   e 
 
  2899  gac tca gca gtc ctt gtc gct gat acc caa gaa gag gac ggc gtt gcc aag ggg cag gtt gag gcg gat 
          d   s   a   v   l   v   a   d   t   q   e   e   d   g   v   a   k   g   q   v   e   a   d 
 
  2968  tcg gaa att tgc gtt gcg cat act ggt agt caa gaa gaa ttg gct gag cct gat gct gtc gga tct caa 
          s   e   i   c   v   a   h   t   g   s   q   e   e   l   a   e   p   d   a   v   g   s   q 
 
  3037  act ccc atc gcc tct gct gag gaa acc gaa gtc gga gag gca agc gac agg gaa ggg att gct gag gcg 
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          t   p   i   a   s   a   e   e   t   e   v   g   e   a   s   d   r   e   g   i   a   e   a 
 
  3106  aag gca act gtg tgt gct gat gct gta gat gcc tgc ccc gat caa gtg gag gca ttt gaa att gaa aag 
          k   a   t   v   c   a   d   a   v   d   a   c   p   d   q   v   e   a   f   e   i   e   k 
 
  3175  gtt gaa gac tct atc ttg gat gag ctt caa act gaa ctt aat gcg cca gcg gac aag acc tat gag gat 
          v   e   d   s   i   l   d   e   l   q   t   e   l   n   a   p   a   d   k   t   y   e   d 
 
  3244  gtc ttg gca ttc gat gcc gta tgc tca gag gcg ttg tct gca ttc tat gct gtg ccg agt gat gag acg 
          v   l   a   f   d   a   v   c   s   e   a   l   s   a   f   y   a   v   p   s   d   e   t 
 
  3313  cac ttt aaa gtg tgt gga ttc tat tcg cct gct ata gag cgc act aat tgt tgg ctg cgt tct act ttg 
          h   f   k   v   c   g   f   y   s   p   a   i   e   r   t   n   c   w   l   r   s   t   l 
 
  3382  ata gta atg cag agt cta cct ttg gaa ttt aaa gac ttg gag atg caa aag ctc tgg ttg tct tac aag 
          i   v   m   q   s   l   p   l   e   f   k   d   l   e   m   q   k   l   w   l   s   y   k 
 
  3451  gcc ggc tat gac caa tgc ttt gtg gac aaa cta gtt aag agc gtg ccc aag tct att atc ctt cca caa 
          a   g   y   d   q   c   f   v   d   k   l   v   k   s   v   p   k   s   i   i   l   p   q 
 
  3520  ggt ggt tat gtg gca gat ttt gcc tat ttc ttt cta agc cag tgt agc ttt aaa gct tat gct aac tgg 
          g   g   y   v   a   d   f   a   y   f   f   l   s   q   c   s   f   k   a   y   a   n   w 
 
  3589  cgt tgt tta gag tgt gac atg gag tta aag ctt caa ggc ttg gac gcc atg ttt ttc tat ggg gac gtt 
          r   c   l   e   c   d   m   e   l   k   l   q   g   l   d   a   m   f   f   y   g   d   v 
 
  3658  gtg tct cat atg tgc aag tgt ggt aat agc atg acc ttg ttg tct gca gat ata ccc tac act ttg cat 
          v   s   h   m   c   k   c   g   n   s   m   t   l   l   s   a   d   i   p   y   t   l   h 
 
  3727  ttt gga gtg cga gat gat aag ttt tgc gct ttt tac acg cca aga aag gtc ttt agg gct gct tgt gcg 
          f   g   v   r   d   d   k   f   c   a   f   y   t   p   r   k   v   f   r   a   a   c   a 
 
  3796  gta gat gtt aat gat tgt cac tct atg gct gta gta gag ggc aag caa att gat ggt aaa gtg gtt acc 
          v   d   v   n   d   c   h   s   m   a   v   v   e   g   k   q   i   d   g   k   v   v   t 
 
  3865  aaa ttt att ggt gac aaa ttt gat ttt atg gtg ggt tac ggg atg aca ttt agt atg tct cct ttt gaa 
          k   f   i   g   d   k   f   d   f   m   v   g   y   g   m   t   f   s   m   s   p   f   e 
 
  3934  ctc gcc cag tta tat ggt tca tgt ata aca cca aat gtt tgt ttt gtt aaa gga gat gtt ata aag gtt 
          l   a   q   l   y   g   s   c   i   t   p   n   v   c   f   v   k   g   d   v   i   k   v 
 
  4003  gtt cgc tta gtt aat gct gaa gtc att gtt aac cct gct aat ggg cgt atg gct cat ggt gca ggt gtt 
          v   r   l   v   n   a   e   v   i   v   n   p   a   n   g   r   m   a   h   g   a   g   v 
 
  4072  gca ggt gct ata gct gaa aag gcg ggc agt gct ttt att aaa gaa acc tcc gat atg gtg aag gct cag 
          a   g   a   i   a   e   k   a   g   s   a   f   i   k   e   t   s   d   m   v   k   a   q 
LA16                            ... 
NC2                             g..(E)  
  4141  ggc gtt tgc cag gtt ggt gaa tgc tat gaa tct gcc ggt ggt aag tta tgt aaa aag gtg ctt aac att 
          g   v   c   q   v   g   e   c   y   e   s   a   g   g   k   l   c   k   k   v   l   n   i 
 
  4210  gta ggg cca gat gcg cga ggg cat ggc aag caa tgc tat tca ctt tta gag cgt gct tat cag cat att 
          v   g   p   d   a   r   g   h   g   k   q   c   y   s   l   l   e   r   a   y   q   h   i 
 
  4279  aat aag tgt gac aat gtt gtc act act tta att tcg gct ggt ata ttt agt gtg cct act gat gtc tcc 
          n   k   c   d   n   v   v   t   t   l   i   s   a   g   i   f   s   v   p   t   d   v   s 
 
  4348  cta act tac tta ctt ggt gta gtg aca aag aat gtc att ctt gtc agt aac aac cag gat gat ttt gat 
          l   t   y   l   l   g   v   v   t   k   n   v   i   l   v   s   n   n   q   d   d   f   d 
 
  4417  gtg ata gag aag tgt cag gtg acc tcc gtt gct ggt acc aaa gcg cta tca ctt caa ttg gcc aaa aat 
          v   i   e   k   c   q   v   t   s   v   a   g   t   k   a   l   s   l   q   l   a   k   n 
 
  4486  ttg tgc cgt gat gta aag ttt gtg acg aat gca tgt agt tcg ctt ttt agt gaa tct tgc ttt gtc tca 
          l   c   r   d   v   k   f   v   t   n   a   c   s   s   l   f   s   e   s   c   f   v   s 
 
  4555  agc tat gat gtg ttg cag gaa gtt gaa gcg ctg cga cat gat ata caa ttg gat gat gat gct cgt gtc 
          s   y   d   v   l   q   e   v   e   a   l   r   h   d   i   q   l   d   d   d   a   r   v 
 
  4624  ttt gtg cag gct aat atg gac tgt ctg ccc aca gac tgg cgt ctc gtt aac aaa ttt gat agt gtt gat 
          f   v   q   a   n   m   d   c   l   p   t   d   w   r   l   v   n   k   f   d   s   v   d 
 
  4693  ggt gtt aga acc att aag tat ttt gaa tgc ccg ggc ggg att ttt gta tcc agc cag ggc aaa aag ttt 
          g   v   r   t   i   k   y   f   e   c   p   g   g   i   f   v   s   s   q   g   k   k   f 
 
  4762  ggt tat gtt cag aat ggt tca ttt aag gag gcg agt gtt agc caa ata agg gct tta ctc gct aat aag 
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          g   y   v   q   n   g   s   f   k   e   a   s   v   s   q   i   r   a   l   l   a   n   k 
 
  4831  gtt gat gtc ttg tgt act gtt gat ggt gtt aac ttc cgc tcc tgc tgc gta gca gag ggt gaa gtt ttt 
          v   d   v   l   c   t   v   d   g   v   n   f   r   s   c   c   v   a   e   g   e   v   f 
 
  4900  ggc aag aca tta ggt tca gtc ttt tgt gat ggc ata aat gtc acc aaa gtt agg tgt agt gcc att tac 
          g   k   t   l   g   s   v   f   c   d   g   i   n   v   t   k   v   r   c   s   a   i   y 
 
  4969  aag ggt aag gtt ttc ttt cag tac agt gat ttg tcc gag gca gat ctt gtg gct gtt aaa gat gcc ttt 
          k   g   k   v   f   f   q   y   s   d   l   s   e   a   d   l   v   a   v   k   d   a   f 
 
  5038  ggt ttt gat gaa cca caa ctg ctg aag tac tac act atg ctt ggc atg tgt aag tgg tca gta gtt gtt 
          g   f   d   e   p   q   l   l   k   y   y   t   m   l   g   m   c   k   w   s   v   v   v 
LA16                                                                                c..(P) 
NC2                                                                                 c..(P) 
  5107  tgt ggc aat tat ttt gct ttc aag cag tca aat aat aat tgc tat ata aat gtg gca tgt tta atg ctg 
          c   g   n   y   f   a   f   k   q   s   n   n   n   c   y   i   n   v   a   c   l   m   l 
 
  5176  caa cac ttg agt tta aag ttt cct aag tgg caa tgg caa gag gct tgg aac gag ttc cgc tct ggt aaa 
          q   h   l   s   l   k   f   p   k   w   q   w   q   e   a   w   n   e   f   r   s   g   k 
 
  5245  cca cta agg ttt gtg tcc ttg gta tta gca aag ggc agc ttt aaa ttt aat gaa cct tct gat tct atc 
          p   l   r   f   v   s   l   v   l   a   k   g   s   f   k   f   n   e   p   s   d   s   i 
 
  5314  gat ttt atg cgt gtg gtg cta cgt gaa gca gat ttg agt ggt gcc acg tgc aat ttg gaa ttt gtt tgt 
          d   f   m   r   v   v   l   r   e   a   d   l   s   g   a   t   c   n   l   e   f   v   c 
 
  5383  aaa tgt ggt gtg aag caa gag cag cgc aaa ggt gtt gac gct gtt atg cat ttt ggt acg ttg gat aaa 
          k   c   g   v   k   q   e   q   r   k   g   v   d   a   v   m   h   f   g   t   l   d   k 
 
  5452  ggt gat ctt gtc agg ggt tat aat atc gca tgt acg tgc ggt agt aaa ctt gtg cat tgc acc caa ttt 
          g   d   l   v   r   g   y   n   i   a   c   t   c   g   s   k   l   v   h   c   t   q   f 
 
  5521  aac gta cca ttt tta att tgc tcc aac aca cca gag ggt agg aaa ctg ccc gac gat gtt gtt gca gct 
          n   v   p   f   l   i   c   s   n   t   p   e   g   r   k   l   p   d   d   v   v   a   a 
 
  5590  aat att ttt act ggt ggt agt gtg ggc cat tac acg cat gtg aaa tgt aaa ccc aag tac cag ctt tat 
          n   i   f   t   g   g   s   v   g   h   y   t   h   v   k   c   k   p   k   y   q   l   y 
 
  5659  gat gct tgt aat gtt aat aag gtt tcg gag gct aag ggt aat ttt acc gat tgc ctc tac ctt aaa aat 
          d   a   c   n   v   n   k   v   s   e   a   k   g   n   f   t   d   c   l   y   l   k   n 
 
  5728  tta aag caa act ttt tcg tct gtg ctg acg act ttt tat tta gat gat gta aag tgt gtg gag tat aag 
          l   k   q   t   f   s   s   v   l   t   t   f   y   l   d   d   v   k   c   v   e   y   k 
 
  5797  cca gat tta tcg cag tat tac tgt gag tct ggt aaa tat tat aca aaa ccc att att aag gcc caa ttt 
          p   d   l   s   q   y   y   c   e   s   g   k   y   y   t   k   p   i   i   k   a   q   f 
 
  5866  aga aca ttt gag aag gtt gat ggt gtc tat acc aac ttt aaa ttg gtg gga cat agt att gct gaa aaa 
          r   t   f   e   k   v   d   g   v   y   t   n   f   k   l   v   g   h   s   i   a   e   k 
 
  5935  ctc aat gct aag ctg gga ttt gat tgt aat tct ccc ttt gtg gag tat aaa att aca gag tgg cca aca 
          l   n   a   k   l   g   f   d   c   n   s   p   f   v   e   y   k   i   t   e   w   p   t 
 
  6004  gct act gga gat gtg gtg ttg gct agt gat gat ttg tat gta agt cgg tac tca agc ggg tgc att act 
          a   t   g   d   v   v   l   a   s   d   d   l   y   v   s   r   y   s   s   g   c   i   t 
LA16                                                        ..g 
NC2                                                         ..g 
  6073  ttt ggt aaa ccg gtt gtc tgg ctt ggc cat gag gaa gca tcg ctg aaa tct ctc aca tat ttt aat aga 
          f   g   k   p   v   v   w   l   g   h   e   e   a   s   l   k   s   l   t   y   f   n   r 
 
  6142  cct agt gtc gtt tgt gaa aat aaa ttt aat gtg ttg ccc gtt gat gtc agt gaa ccc acg gac aag ggg 
          p   s   v   v   c   e   n   k   f   n   v   l   p   v   d   v   s   e   p   t   d   k   g 
 
  6211  cct gtg cct gct gca gtc ctt gtt acc ggc gtc cct gga gct gat gcg tca gct ggt gcc ggt att gcc 
          p   v   p   a   a   v   l   v   t   g   v   p   g   a   d   a   s   a   g   a   g   i   a 
 
  6280  aag gag caa aaa gcc tgt gct tct gct agt gtg gag gat cag gtt gtt acg gag gtt cgt caa gag cca 
          k   e   q   k   a   c   a   s   a   s   v   e   d   q   v   v   t   e   v   r   q   e   p 
 
  6349  tct gtt tca gct gct gat gtc aaa gag gtt aaa ttg aat ggt gtt aaa aag cct gtt aag gtg gaa ggt 
          s   v   s   a   a   d   v   k   e   v   k   l   n   g   v   k   k   p   v   k   v   e   g 
 
  6418  agt gtg gtt gtt aat gat ccc act agc gaa acc aaa gtt gtt aaa agt ttg tct att gtt gat gtc tat 
          s   v   v   v   n   d   p   t   s   e   t   k   v   v   k   s   l   s   i   v   d   v   y 
 
		 	
34	
  6487  gat atg ttc ctg aca ggg tgt aag tat gtg gtt tgg act gct aat gag ttg tct cga cta gta aat tca 
          d   m   f   l   t   g   c   k   y   v   v   w   t   a   n   e   l   s   r   l   v   n   s 
 
  6556  ccg act gtt agg gag tat gtg aag tgg ggt aag gga aag att gta aca ccc gct aag ttg ttg ttg tta 
          p   t   v   r   e   y   v   k   w   g   k   g   k   i   v   t   p   a   k   l   l   l   l 
LA16                                            .t.(M) 
NC2                                             .t.(M) 
  6625  aga gat gag aag caa gag ttc gta gcg cca aaa gta gtc aag gcg aaa gct att gcc tgc tat tgt gct 
          r   d   e   k   q   e   f   v   a   p   k   v   v   k   a   k   a   i   a   c   y   c   a 
 
  6694  gtg aag tgg ttt ctc ctc tat tgt ttt agt tgg ata aag ttt aat act gat aat aag gtt ata tac acc 
          v   k   w   f   l   l   y   c   f   s   w   i   k   f   n   t   d   n   k   v   i   y   t 
 
  6763  aca gaa gta gct tca aag ctt act ttc aag ttg tgc tgt ttg gcc ttt aag aat gcc tta cag acg ttt 
          t   e   v   a   s   k   l   t   f   k   l   c   c   l   a   f   k   n   a   l   q   t   f 
 
  6832  aat tgg agc gtt gtg tct agg ggc ttt ttc cta gtt gca acg gtc ttt tta tta tgg ttt aac ttt ttg 
          n   w   s   v   v   s   r   g   f   f   l   v   a   t   v   f   l   l   w   f   n   f   l 
 
  6901  tat gct aat gtt att ttg agt gac ttc tat ttg cct aat att ggg cct ctc cct acg ttt gtg gga cag 
          y   a   n   v   i   l   s   d   f   y   l   p   n   i   g   p   l   p   t   f   v   g   q 
 
  6970  ata gtt gcg tgg ttt aag act aca ttt ggt gtg tca acc atc tgt gat ttc tac cag gtg acg gat ttg 
          i   v   a   w   f   k   t   t   f   g   v   s   t   i   c   d   f   y   q   v   t   d   l 
 
  7039  ggc tat aga agt tcg ttt tgt aat gga agt atg gta tgt gaa cta tgc ttc tca ggt ttt gat atg ctg 
          g   y   r   s   s   f   c   n   g   s   m   v   c   e   l   c   f   s   g   f   d   m   l 
LA16                                    .a.(E) 
NC2                                     ... 
  7108  gac aac tat gat gct ata aat gtt gtt caa cac gtt gta gat agg cgt ttg tcc ttt gac tat att agc 
          d   n   y   d   a   i   n   v   v   q   h   v   v   d   r   r   l   s   f   d   y   i   s 
 
  7177  cta ttt aaa tta gta gtt gag ctt gta atc ggc tac tct ctt tat act gtg tgc ttc tac cca ctg ttt 
          l   f   k   l   v   v   e   l   v   i   g   y   s   l   y   t   v   c   f   y   p   l   f 
 
  7246  gtc ctt att gga atg cag ttg ttg acc aca tgg ttg cct gaa ttc ttt atg ctg gag act atg cat tgg 
          v   l   i   g   m   q   l   l   t   t   w   l   p   e   f   f   m   l   e   t   m   h   w 
 
  7315  agt gct cgt ttg ttt gtg ttt gtt gcc aat atg ctt cca gct ttt acg tta ctg cga ttt tac atc gtg 
          s   a   r   l   f   v   f   v   a   n   m   l   p   a   f   t   l   l   r   f   y   i   v 
 
  7384  gtg aca gct atg tat aag gtc tat tgt ctt tgt aga cat gtt atg tat gga tgt agt aag cct ggt tgc 
          v   t   a   m   y   k   v   y   c   l   c   r   h   v   m   y   g   c   s   k   p   g   c 
 
  7453  ttg ttt tgt tat aag aga aac cgt agt gtc cgt gtt aag tgt agc acc gtt gtt ggt ggt tca cta cgc 
          l   f   c   y   k   r   n   r   s   v   r   v   k   c   s   t   v   v   g   g   s   l   r 
 
  7522  tat tac gat gta atg gct aac ggc ggc aca ggt ttc tgt aca aag cac cag tgg aac tgt ctt aat tgc 
          y   y   d   v   m   a   n   g   g   t   g   f   c   t   k   h   q   w   n   c   l   n   c 
 
  7591  aat tcc tgg aaa cca ggc aat aca ttc ata act cat gaa gca gcg gcg gac ctc tct aag gag ttg aaa 
          n   s   w   k   p   g   n   t   f   i   t   h   e   a   a   a   d   l   s   k   e   l   k 
 
  7660  cgc cct gtg aat cca aca gat tct gct tat tac tcg gtc aca gag gtt aag cag gtt ggt tgt tcc atg 
          r   p   v   n   p   t   d   s   a   y   y   s   v   t   e   v   k   q   v   g   c   s   m 
 
  7729  cgt ttg ttc tac gag aga gat gga cag cgt gtt tat gat gat gtt aat gct agt ttg ttt gtg gac atg 
          r   l   f   y   e   r   d   g   q   r   v   y   d   d   v   n   a   s   l   f   v   d   m 
 
  7798  aat ggt ctg ctg cat tct aaa gtt aaa ggt gtg cct gaa acg cat gtt gtg gtt gtt gag aat gaa gct 
          n   g   l   l   h   s   k   v   k   g   v   p   e   t   h   v   v   v   v   e   n   e   a 
 
  7867  gat aaa gct ggt ttt ctc ggc gcc gca gtg ttt tat gca caa tcg ctc tac aga cct atg ttg atg gtg 
          d   k   a   g   f   l   g   a   a   v   f   y   a   q   s   l   y   r   p   m   l   m   v 
 
  7936  gaa aag aaa tta ata act acc gcc aac act ggt ttg tct gtt agt cga act atg ttt gac ctt tat gta 
          e   k   k   l   i   t   t   a   n   t   g   l   s   v   s   r   t   m   f   d   l   y   v 
 
  8005  gat tca ttg ctg aac gtc ctc gac gtg gat cgc aag agt cta aca agt ttt gta aat gct gcg cac aac 
          d   s   l   l   n   v   l   d   v   d   r   k   s   l   t   s   f   v   n   a   a   h   n 
 
  8074  tct cta aag gag ggt gtt cag ctt gaa caa gtt atg gat acc ttt att ggc tgt gcc cga cgt aag tgt 
          s   l   k   e   g   v   q   l   e   q   v   m   d   t   f   i   g   c   a   r   r   k   c 
 
  8143  gct ata gat tct gat gtt gaa acc aag tct att acc aag tcc gtc atg tcg gca gta aat gct ggc gtt 
          a   i   d   s   d   v   e   t   k   s   i   t   k   s   v   m   s   a   v   n   a   g   v 
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  8212  gat ttt acg gat gag agt tgt aat aac ttg gtg cct acc tat gtt aaa agt gac act atc gtt gca gcc 
          d   f   t   d   e   s   c   n   n   l   v   p   t   y   v   k   s   d   t   i   v   a   a 
 
  8281  gat ttg ggt gtt ctt att cag aat aat gct aag cat gta cag gct aat gtt gct aaa gcc gct aat gtg 
          d   l   g   v   l   i   q   n   n   a   k   h   v   q   a   n   v   a   k   a   a   n   v 
 
  8350  gct tgc att tgg tct gtg gat gct ttt aac cag cta tct gct gac tta cag cat agg ctg cga aaa gca 
          a   c   i   w   s   v   d   a   f   n   q   l   s   a   d   l   q   h   r   l   r   k   a 
 
  8419  tgt tca aaa act ggc ttg aag att aag ctt act tat aat aag cag gag gca aat gtt cct att tta act 
          c   s   k   t   g   l   k   i   k   l   t   y   n   k   q   e   a   n   v   p   i   l   t 
 
  8488  aca ccg ttc tct ctt aaa ggg ggc gct gtt ttt agt aga atg tta caa tgg ttg ttt gtt gct aat ttg 
          t   p   f   s   l   k   g   g   a   v   f   s   r   m   l   q   w   l   f   v   a   n   l 
 
  8557  att tgt ttc att gtg ttg tgg gcc ctt atg cca aca tat gca gtg cac aaa tcg gat atg cag ttg cct 
          i   c   f   i   v   l   w   a   l   m   p   t   y   a   v   h   k   s   d   m   q   l   p 
 
  8626  tta tat gcc agt ttt aaa gtt ata gat aat ggt gtg cta agg gat gtg tct gtt act gac gca tgc ttc 
          l   y   a   s   f   k   v   i   d   n   g   v   l   r   d   v   s   v   t   d   a   c   f 
 
  8695  gca aac aaa ttt aat caa ttt gat caa tgg tat gag tct act ttt ggt ctt gct tat tac cgc aac tct 
          a   n   k   f   n   q   f   d   q   w   y   e   s   t   f   g   l   a   y   y   r   n   s 
 
  8764  aag gct tgt cct gtt gtg gtt gct gta ata gat caa gac att ggc cat acc tta ttt aat gtt cct acc 
          k   a   c   p   v   v   v   a   v   i   d   q   d   i   g   h   t   l   f   n   v   p   t 
 
  8833  aca gtt tta aga tat gga ttt cat gtg ttg cat ttt ata acc cat gca ttt gct act gat agc gtg cag 
          t   v   l   r   y   g   f   h   v   l   h   f   i   t   h   a   f   a   t   d   s   v   q 
 
  8902  tgt tac acg cca cat atg caa atc ccc tat gat aat ttc tat gct agt ggt tgc gtg ttg tca tcc ctc 
          c   y   t   p   h   m   q   i   p   y   d   n   f   y   a   s   g   c   v   l   s   s   l 
 
  8971  tgt act atg ctt gcg cat gca gat gga acc ccg cat cct tat tgt tat aca ggg ggt gtt atg cac aat 
          c   t   m   l   a   h   a   d   g   t   p   h   p   y   c   y   t   g   g   v   m   h   n 
 
  9040  gcc tct ctg tat agt tct ttg gct cct cat gtc cgt tat aac ctg gct agt tca aat ggt tat ata cgt 
          a   s   l   y   s   s   l   a   p   h   v   r   y   n   l   a   s   s   n   g   y   i   r 
 
  9109  ttt ccc gaa gtg gtt agt gaa ggc att gtg cgt gtt gtg cgc act cgc tct atg acc tac tgc agg gtt 
          f   p   e   v   v   s   e   g   i   v   r   v   v   r   t   r   s   m   t   y   c   r   v 
 
  9178  ggt tta tgt gag gag gcc gag gag ggt atc tgc ttt aat ttt aat cgt tca tgg gta ttg aac aac ccg 
          g   l   c   e   e   a   e   e   g   i   c   f   n   f   n   r   s   w   v   l   n   n   p 
 
  9247  tat tat agg gcc atg cct gga act ttt tgt ggt agg aat gct ttt gat tta ata cat caa gtt tta gga 
          y   y   r   a   m   p   g   t   f   c   g   r   n   a   f   d   l   i   h   q   v   l   g 
 
  9316  gga tta gtg cgg cct att gat ttc ttt gcc tta acg gcg agt tca gtg gct ggt gct atc ctt gca att 
          g   l   v   r   p   i   d   f   f   a   l   t   a   s   s   v   a   g   a   i   l   a   i 
 
  9385  att gtc gtt ttg gct ttc tat tat tta ata aag ctt aaa cgt gcc ttt ggt gac tac act agt gtt gtg 
          i   v   v   l   a   f   y   y   l   i   k   l   k   r   a   f   g   d   y   t   s   v   v 
 
  9454  gtt atc aat gta att gtg tgg tgt ata aat ttt ctg atg ctt ttt gtg ttt cag gtt tat ccc aca ttg 
          v   i   n   v   i   v   w   c   i   n   f   l   m   l   f   v   f   q   v   y   p   t   l 
 
  9523  tct tgt tta tat gct tgt ttt tat ttc tac aca acg ctt tat ttc cct tcg gag ata agt gtt gtt atg 
          s   c   l   y   a   c   f   y   f   y   t   t   l   y   f   p   s   e   i   s   v   v   m 
 
  9592  cat ttg caa tgg ctt gtc atg tat ggt gct att atg ccc ttg tgg ttt tgc att att tac gtg gca gtc 
          h   l   q   w   l   v   m   y   g   a   i   m   p   l   w   f   c   i   i   y   v   a   v 
 
  9661  gtt gtt tca aac cat gca ttg tgg ttg ttc tct tac tgc cgc aaa att ggt acc gag gtt cgt agt gac 
          v   v   s   n   h   a   l   w   l   f   s   y   c   r   k   i   g   t   e   v   r   s   d 
 
  9730  ggc aca ttt gag gaa atg gcc ctt act acc ttt atg att act aaa gaa tct tat tgt aag ttg aaa aat 
          g   t   f   e   e   m   a   l   t   t   f   m   i   t   k   e   s   y   c   k   l   k   n 
LA16                                                        ... 
NC2                                                         ..g(S) 
  9799  tct gtt tct gat gtt gct ttt aac agg tac ttg agt ctt tat aac aag tat cgt tat ttt agt ggc aaa 
          s   v   s   d   v   a   f   n   r   y   l   s   l   y   n   k   y   r   y   f   s   g   k 
LA16                        ... 
NC2                         .g.(G) 
  9868  atg gat act gcc gct tat aga gag gct gcc tgt tca caa ctg gca aag gca atg gaa aca ttt aac cat 
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          m   d   t   a   a   y   r   e   a   a   c   s   q   l   a   k   a   m   e   t   f   n   h 
 
  9937  aat aat ggt aat gat gtt ctc tat cag cct cca acc gcc tct gtt act aca tca ttt tta cag tct ggt 
          n   n   g   n   d   v   l   y   q   p   p   t   a   s   v   t   t   s   f   l   q   s   g 
 
 10006  ata gtg aag atg gtg tcg ccc acc tct aaa gtg gag cct tgt att gtt agt gtt act tat ggt aac atg 
          i   v   k   m   v   s   p   t   s   k   v   e   p   c   i   v   s   v   t   y   g   n   m 
 
 10075  aca ctt aat ggg ttg tgg ttg gat gat aaa gtt tat tgc cca aga cat gtt atc tgt tct tca gct gac 
          t   l   n   g   l   w   l   d   d   k   v   y   c   p   r   h   v   i   c   s   s   a   d 
 
 10144  atg aca gac cct gat tat cct aat ttg ctt tgt aga gtg aca tca agt gat ttt tgt gtt atg tct ggt 
          m   t   d   p   d   y   p   n   l   l   c   r   v   t   s   s   d   f   c   v   m   s   g 
LA16                                        ... 
NC2                                         a..(I) 
 10213  cgt atg agc ctt act gta atg tct tat caa atg cag ggc tgc caa ctt gtt ttg act gtt aca ctg caa 
          r   m   s   l   t   v   m   s   y   q   m   q   g   c   q   l   v   l   t   v   t   l   q 
 
 10282  aat cct aac acg cct aag tat tcc ttc ggt gtt gtt aag cct ggt gag aca ttt act gta ctg gct gca 
          n   p   n   t   p   k   y   s   f   g   v   v   k   p   g   e   t   f   t   v   l   a   a 
 
 10351  tac aat ggc aga cct caa gga gcc ttc cat gtt acg ctt cgt agt agc cat acc ata aag ggc tcc ttt 
          y   n   g   r   p   q   g   a   f   h   v   t   l   r   s   s   h   t   i   k   g   s   f 
 
 10420  cta tgt gga tcc tgc ggt tct gta gga tat gtt tta act ggc gat agt gta cga ttt gtt tat atg cat 
          l   c   g   s   c   g   s   v   g   y   v   l   t   g   d   s   v   r   f   v   y   m   h 
 
 10489  cag cta gag ttg agt act ggt tgt cat acc ggt act gac ttt agt ggg aac ttt tat ggt ccc tat aga 
          q   l   e   l   s   t   g   c   h   t   g   t   d   f   s   g   n   f   y   g   p   y   r 
 
 10558  gat gcg caa gtt gta caa ttg cct gtt cag gat tat acg cag act gtt aat gtt gta gct tgg ctt tat 
          d   a   q   v   v   q   l   p   v   q   d   y   t   q   t   v   n   v   v   a   w   l   y 
 
 10627  gct gct att ttt aac aga tgc aac tgg ttt gtg caa agt gat agt tgt tcc ctg gag gag ttt aat gtt 
          a   a   i   f   n   r   c   n   w   f   v   q   s   d   s   c   s   l   e   e   f   n   v 
 
 10696  tgg gct atg acc aat ggt ttt agc tca atc aaa gcc gat ctt gtc ttg gat gcg ctt gct tct atg aca 
          w   a   m   t   n   g   f   s   s   i   k   a   d   l   v   l   d   a   l   a   s   m   t 
LA16                                        ..t 
NC2                                         ..t 
 10765  ggc gtt aca gtt gaa cag gtg ttg gcc gct att aag agg ctg cat tct gga ttc cag ggc aaa caa att 
          g   v   t   v   e   q   v   l   a   a   i   k   r   l   h   s   g   f   q   g   k   q   i 
 
 10834  tta ggt agt tgt gtg ctt gaa gat gag ctg aca cca agt gat gtt tat caa caa cta gct ggt gtc aag 
          l   g   s   c   v   l   e   d   e   l   t   p   s   d   v   y   q   q   l   a   g   v   k 
 
 10903  cta cag tca aag cgc aca aga gtt ata aaa ggt aca tgt tgc tgg ata ttg gct tca acg ttt ttg ttc 
          l   q   s   k   r   t   r   v   i   k   g   t   c   c   w   i   l   a   s   t   f   l   f 
 
 10972  tgt agc att atc tca gca ttt gta aaa tgg act atg ttt atg tat gtt act acc cat atg ttg gga gtg 
          c   s   i   i   s   a   f   v   k   w   t   m   f   m   y   v   t   t   h   m   l   g   v 
 
 11041  aca ttg tgt gca ctt tgt ttt gta agc ttt gct atg ttg ttg atc aag cat aag cat ttg tat tta act 
          t   l   c   a   l   c   f   v   s   f   a   m   l   l   i   k   h   k   h   l   y   l   t 
 
 11110  atg tat att atg cct gtg tta tgc aca ctg ttt tac acc aac tat ttg gtt gtg tac aaa cag agt ttt 
          m   y   i   m   p   v   l   c   t   l   f   y   t   n   y   l   v   v   y   k   q   s   f 
 
 11179  aga ggt cta gct tat gct tgg ctt tca cac ttt gtc cct gct gta gat tat aca tat atg gat gaa gtt 
          r   g   l   a   y   a   w   l   s   h   f   v   p   a   v   d   y   t   y   m   d   e   v 
 
 11248  tta tat ggt gtt gtg ttg cta gta gct atg gtg ttt gtt acc atg cgt agc ata aac cac gac gtc ttt 
          l   y   g   v   v   l   l   v   a   m   v   f   v   t   m   r   s   i   n   h   d   v   f 
 
 11317  tct att atg ttc ttg gtt ggt aga ctt gtc agc ctg gta tcc atg tgg tat ttt gga gcc aat tta gag 
          s   i   m   f   l   v   g   r   l   v   s   l   v   s   m   w   y   f   g   a   n   l   e 
 
 11386  gaa gag gta cta ttg ttc ctc aca tcc cta ttt ggc acg tac aca tgg act act atg ttg tca ttg gct 
          e   e   v   l   l   f   l   t   s   l   f   g   t   y   t   w   t   t   m   l   s   l   a 
 
 11455  acc gct aag gtt att gct aaa tgg ttg gct gtg aat gtc ttg tac ttc aca gac gta ccg caa att aaa 
          t   a   k   v   i   a   k   w   l   a   v   n   v   l   y   f   t   d   v   p   q   i   k 
 
 11524  tta gtt ctt ttg agc tac ttg tgt att ggt tat gtg tgt tgt tgt tat tgg gga atc ttg tca ctc ctt 
          l   v   l   l   s   y   l   c   i   g   y   v   c   c   c   y   w   g   i   l   s   l   l 
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 11593  aat agc att ttt agg atg cca ttg ggc gtc tac aat tat aaa atc tcc gtt cag gag tta cgt tat atg 
          n   s   i   f   r   m   p   l   g   v   y   n   y   k   i   s   v   q   e   l   r   y   m 
 
 11662  aat gct aat ggc ttg cgc cca cct aga aat agt ttt gag gcc ctg atg ctt aat ttt aag ctg ttg gga 
          n   a   n   g   l   r   p   p   r   n   s   f   e   a   l   m   l   n   f   k   l   l   g 
 
 11731  att ggt ggt gtg cca gtc att gaa gta tct caa att caa tca aga ttg acg gat gtt aaa tgt gct aat 
          i   g   g   v   p   v   i   e   v   s   q   i   q   s   r   l   t   d   v   k   c   a   n 
 
 11800  gtt gtg ttg ctt aat tgc ctc cag cac ttg cat att gca tct aat tct aag ttg tgg cag tat tgt agt 
          v   v   l   l   n   c   l   q   h   l   h   i   a   s   n   s   k   l   w   q   y   c   s 
 
 11869  act ttg cac aat gaa ata ctg gct aca tct gat ttg agc gtg gcc ttc gat aag ttg gct cag ctc tta 
          t   l   h   n   e   i   l   a   t   s   d   l   s   v   a   f   d   k   l   a   q   l   l 
 
 11938  gtt gtt tta ttt gct aat cca gca gca gtg gat agc aag tgc ctt gca agt att gaa gaa gtg agc gat 
          v   v   l   f   a   n   p   a   a   v   d   s   k   c   l   a   s   i   e   e   v   s   d 
 
 12007  gat tac gtt cgc gac aat act gtc ttg caa gcc tta cag agt gaa ttt gtt aat atg gct agc ttc gtt 
          d   y   v   r   d   n   t   v   l   q   a   l   q   s   e   f   v   n   m   a   s   f   v 
 
 12076  gag tat gaa ctt gct aag aag aat cta gat gag gct aag gct agc ggc tct gcc aat caa cag cag att 
          e   y   e   l   a   k   k   n   l   d   e   a   k   a   s   g   s   a   n   q   q   q   i 
 
 12145  aag cag cta gag aag gcg tgt aat att gct aag tca gca tat gag cgc gac aga gct gtt gct cgt aag 
          k   q   l   e   k   a   c   n   i   a   k   s   a   y   e   r   d   r   a   v   a   r   k 
 
 12214  ctg gaa cgt atg gct gat tta gct ctt aca aac atg tat aaa gaa gct aga att aat gat aag aag agt 
          l   e   r   m   a   d   l   a   l   t   n   m   y   k   e   a   r   i   n   d   k   k   s 
 
 12283  aag gta gtg tct gca ttg caa acc atg ctc ttt agt atg gtg cgt aag cta gat aac caa gct ctt aat 
          k   v   v   s   a   l   q   t   m   l   f   s   m   v   r   k   l   d   n   q   a   l   n 
 
 12352  tct att tta gat aat gca gtt aag ggt tgt gta cct ttg aat gca ata cca tca ttg act tcg aac act 
          s   i   l   d   n   a   v   k   g   c   v   p   l   n   a   i   p   s   l   t   s   n   t 
 
 12421  ctg act ata ata gtg cca gat aag cag gtt ttt gat cag gtt gtg gat aat gtg tat gtc acc tat gct 
          l   t   i   i   v   p   d   k   q   v   f   d   q   v   v   d   n   v   y   v   t   y   a 
 
 12490  ggg aat gta tgg cat ata cag ttt att caa gat gct gat ggt gct gtt aaa caa ttg aat gag ata gat 
          g   n   v   w   h   i   q   f   i   q   d   a   d   g   a   v   k   q   l   n   e   i   d 
 
 12559  gtt aat tca acc tgg cct cta gtc att gct gca aat agg cat aat gaa gtg tct act gtt gtt ttg cag 
          v   n   s   t   w   p   l   v   i   a   a   n   r   h   n   e   v   s   t   v   v   l   q 
 
 12628  aac aat gag ttg atg cct cag aag ttg aga act cag gtt gtc aat agt ggc tca gat atg aat tgt aat 
          n   n   e   l   m   p   q   k   l   r   t   q   v   v   n   s   g   s   d   m   n   c   n 
 
 12697  act cct acc cag tgt tac tat aat act act ggc acg ggt aag att gtg tat gct ata ctt agt gac tgt 
          t   p   t   q   c   y   y   n   t   t   g   t   g   k   i   v   y   a   i   l   s   d   c 
 
 12766  gat ggt ctc aag tac act aag ata gta aaa gaa gat gga aat tgt gtt gtt ttg gaa ttg gat cct ccc 
          d   g   l   k   y   t   k   i   v   k   e   d   g   n   c   v   v   l   e   l   d   p   p 
LA16            ...    
NC2             ..g 
 12835  tgt aag ttt tct gtt cag gat gtg aag ggc ctt aaa att aag tac ctt tac ttt gtg aag ggg tgt aat 
          c   k   f   s   v   q   d   v   k   g   l   k   i   k   y   l   y   f   v   k   g   c   n 
 
 12904  aca ctg gct aga ggc tgg gtt gta ggc acc tta tcc tcg aca gtg aga ttg cag gcg ggt acg gca act 
          t   l   a   r   g   w   v   v   g   t   l   s   s   t   v   r   l   q   a   g   t   a   t 
 
 12973  gag tat gcc tcc aac tct gca ata ctg tcg ctg tgt gcg ttt tct gta gat cct aag aaa acg tac ttg 
          e   y   a   s   n   s   a   i   l   s   l   c   a   f   s   v   d   p   k   k   t   y   l 
 
 13042  gat tat ata aaa cag ggt gga gtt ccc gtt act aat tgt gtt aag atg tta tgt gac cat gct ggc act 
          d   y   i   k   q   g   g   v   p   v   t   n   c   v   k   m   l   c   d   h   a   g   t 
LA16                                                                        .a.(Y) 
NC2 
 13111  ggt atg gcc att act att aag ccg gag gca acc act aat cag gat tct tat ggt ggt gct tcc gtt tgt 
          g   m   a   i   t   i   k   p   e   a   t   t   n   q   d   s   y   g   g   a   s   v   c 
 
 13180  ata tat tgc cgc tcg cgt gtt gaa cat cca gat gtt gat gga ttg tgc aaa tta cgc ggc aag ttt gtc 
          i   y   c   r   s   r   v   e   h   p   d   v   d   g   l   c   k   l   r   g   k   f   v 
 
 13249  caa gtg ccc tta ggc ata aaa gat cct gtg tca tat gtg ttg acg cat gat gtt tgt cag gtt tgt ggc 
          q   v   p   l   g   i   k   d   p   v   s   y   v   l   t   h   d   v   c   q   v   c   g 
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 13318  ttt tgg cga gat ggt agc tgt tcc tgt gta ggc aca ggc tcc cag ttt cag tca aaa gac acg aac ttt 
          f   w   r   d   g   s   c   s   c   v   g   t   g   s   q   f   q   s   k   d   t   n   f 
 
 13387  tta aac ggg ttc ggg gta caa gtg taa 
          l   n   g   f   g   v   q   v   - 
LA16            ..a 
NC2             ..a 
 
Comparing Mutations Located in ORF1A from LA16 and NC2 
 
 To compare the mutations identified in the viral genome (Figure 10) a table was 
constructed (Table 1). Table 1 lists the mutated nucleotide position in the viral genome, the 
amino acid change and the type of mutation that resulted. The nucleotide position that was 
entered into the table was obtained from the sequence of ORF1A that starts with the first “atg” 
present in the first open reading frame. This corresponds to nucleotide number 210 in the full 
viral genome that is located in appendix. In assessing the location of the mutations, LA16 
contains mutations in Nsp3 and Nsp10. LA16 has shown to have a more significant TS 
phenotype, assessed by a reduction in titer and plaque size, indicating further that these 
mutations in Nsp3 and Nsp10 are important (Figure 7&8).  It is interesting that of the six 
mutations identified in NC2 that resulted in an amino acid change, three of these mutations are 
conservative. Conservative mutations are defined as mutations that result in an amino acid 
change which conserves the same amino acid charge but has a slightly different structure (Table 
1). These results indicate NC2 and LA16 contain different attenuating mutations. The role of 
these mutations in conferring the TS phenotype could be evaluated using reverse genetics.  
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TABLE 1. Table of nucleotide and amino acid changes in the genomic sequences of LA16 
and NC2. Genomic sequence from ORF1A was analyzed and the nucleotide changes that 
resulted in amino acid changes are listed. Silent mutations are documented in Figure 10. 
Nucleotide position, amino acid position, non-structural protein location and mutation type are 
classified. The location of the nucleotide changes corresponds to the nucleotide sequence of 
ORF1A and not to the entire genomic nucleotide sequence.
Virus Nsp
mutation	
location
Mutated	
Nucleotide	
Positon
Mutated	Amino	Acid
LA16 Nsp3 t	5090	c S→P Polar	to	
Nonpolar
Nsp3 a	6587 t K→M Positively	
Charged	to	
Nonpolar
Nsp3 g	7064	a G→E Polar	to	
Negatively
Charged
Nsp10 g	13094	a G→Y Polar	to	
Nonpolar
NC2 Nsp3 a	4090 g K→E Positively	
Charged to
Negatively	
Charged
Nsp3 t	5090c S→P Polar to	
Nonpolar
Nsp3 a	 6587	 t K→M Positively	
Charged to	
Nonpolar
Nsp4 c	9770 g T→S Conservative
Nsp4 c	9815g A→G Conservative
Nsp5 c	10171	a L→I Conservative
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CHAPTER FOUR 
DISCUSSION AND FUTURE DIRECTIONS 
 Using TS phenotyping has become a staple in virology to better understand many 
unknown pathogens. TS mutants of pathogens allow for the identification of critical genes or 
residues which can be identified as targets for potential vaccine development. In assessing the TS 
phenotype for LA16 and NC2, it was observed that at 33oC, both viruses were able to maintain a 
WT-like plaque size and viral titer (Figure 7A, B). Upon incubating LA16 at 37 oC, I observed a 
drastic change in plaque morphology (Figure 7A). When assessing the plaque morphology, I 
found a heterogeneous population of plaques formed. These plaques range from small to pin-
point in size. Schaad et al. hypothesized that LA16 may contain two different mutations that 
confer the TS phenotype documented41. This heterogeneity does seem to further support why 
LA16 was placed into two complementation groups indicating multiple mutations in different 
areas of the viral genome. This change in morphology was also associated with a reduction in 
viral titer which also helps to support the hypothesis that LA16 confers a TS phenotype. Upon 
quantifying the plaque size of LA16 at 37 oC (Figure 8), there was a significant decrease in 
plaque size when compared to WT, further supporting that the change in morphology may be due 
to the mutations identified in ORF1A. LA16 failed to produce any plaques within the detection 
limit of the plaque assay when incubated at 40oC. When analyzing the sequence of LA16 two 
unique mutations were identified. The first mutation was observed in Nsp3 which resulted in the 
substation of a polar amino acid to a negatively charged amino acid. This could 
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have an effect on the Nsp3 protein stability or structure, but further analysis is required. The 
second mutation found was located in Nsp10. Currently the documented function of Nsp10 is to 
act as a regulator that aides in the efficency of the polyprotein processing45. The amino acid that 
was mutated has been identified a one of several critical residues involved in Nsp10 stability. 
 When assessing the TS phenotype of NC2, I saw that NC2 was able to retain WT-
like plaques at both 33 oC and 37 oC (Figure 7A). This was obviously different than the 
morphology depicted by LA16 at 37 oC. It was only when NC2 was incubated at 40 oC was the 
TS phenotype able to be observed. This reduction in plaque size also correlates with the 
reduction in titer (Figure 7B).  It can be appreciated that although NC2 did present a reduction in 
plaque size at 40oC, there was a homogenous morphology amongst the plaques formed. They 
were all pin-point sized plaques (Figure 7A).  Upon the quantification of the plaques observed, I 
noted NC2 produced significantly smaller plaques compared to WT. The genomic sequencing 
analysis revealed NC2 contained four unique mutations, however, three of the four mutations 
were conservative. The major mutation observed was located in Nsp3, the viral protease. This 
mutation conferred a substitution of a positively charged amino acid to a negatively charged 
amino acid (Table 1).  Since the conservative mutations are located around the same region, 
these mutations could potentially be compensating for the initial Nsp3 mutation. These changes 
in structure potentially could be to help counter act the deleterious mutation, thus allowing NC2 
to not exhibit as drastic of TS phenotype when assessed at 37 oC (Figure 7, 8).  To further 
support my hypothesis that NC2 may have secondary mutations that were induced to stabilize the 
initial attenuating mutation, it can be seen clearly that half of the mutations found in NC2 were 
conservative mutation changes If my hypothesis is true, it may explain why NC2 has much less 
of a significant TS phenotype than that of LA16.  
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 Interestingly, my data supports the previous studies of Schaad et al 41. Using 
complementation analysis Schaad et al. was able to categorize over 20 TS mutants based on the 
location of TS mutations throughout the viral genome (Table 2). Complementation groups A and 
B were mapped to contain mutations in ORF1A. ORF1A was the region where I identified the 
nucleotide changes that are predicted to be responsible for causing the TS phenotype. Over 
twenty years later is seems that this hypothesis was correct when assessing the genomic 
sequencing data. NC2 and LA16 both contained important mutations in Nsp3, supporting the 
rationale for grouping these two mutant strains together.  
  
TABLE 2. Table of TS mutants that have been catorgized based on the location of their 
mutations within the viral genome. Over 2,000 TS mutants were produced following the 
chemical mtagensis of WT MHV. Using complementaiotn analysis Schaad et al. identified 24 
mutants that contained unique mutations41. Highlighted in red are the two mutants that were 
further characterized in my study.  
 
It is important to note that LA16 was the only virus that was added to two complementation 
groups. Schaad et al. hypothesized that this mutant strain actually contained two significant 
muations in ORF1A. This hypothesis does strongly correlate with the images that were taken of 
LA16 at 37oC.  In assessing the images in Figure 7 you can see that there seem to be two 
populations of plaques that formed. These two distict populations may represent viruses that 
contain one of the two hypothesized mutations in ORF1A. It is important to note that although 
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this visual representation does seem to further support previous hypothesis, however further 
analysis will need to be performed.   
 Temparture-sensitive phenotyping has aided in identifying the function of unknown 
CoV Nsps. Donaldson et al. used TS phenotyping to identify a novel attenuating mutation in 
another TS mutant that Schaad et al identified, LA641,45. Deep sequencing of the viral genome 
revealed a mutation in Nsp10. In further assessing the crystal structure of Nsp10, the mutation 
that conferred the TS phenotype was located in an undefined region of the structure45. The amino 
acids located within the undefined region are thought to be critical to maintaining protein 
stability45. In comparing the location of the mutation in LA16, I found the mutation is located 
within this undefined region as well. Therefore, it is possible that the mutation in LA16 also 
affects protein stability.  
 The sequencing results reported in this study revealed that there are many mutations 
located within ORF1A of LA16 and NC2. In order to assess the phenotype of the mutations 
individually, these mutations can be investigated using the MHV reverse genetic system35. A 
reverse-genetics system allows the study of individual mutations by allowing the manipulation of 
a RNA viral genome, using classic genetic techniques35. Mutations are introduced into a cDNA 
version of the RNA genome and using transcription and electroporation, one can produce a 
“designer virus” that has the desired mutation. The production of this designer virus allows one 
to study the phenotype that a single mutation may confer. This same system has also been 
successfully used to identify TS mutation in LA6, as described above45. Hopefully, the 
information obtained in this study will allow the identification of mutations in conserved genes 
that can be applied to a variety of CoVs resulting in protection fro m current and more 
importantly, future strains of CoVs.
		43	
 
 
 
 
 
 
 
 
 
APPENDIX: 
SUPPLEMENTAL FIGURES 
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Figure S1. Full Genomic Sequence Alignment of WT, LA16 and NC2. Using Clone Manager 
I compared the full genomic sequence of LA16, NC2, and WT MHV. Nucleotides that are 
mutated from the WT reference strain are highlighted in orange. Mutations were found 
throughout the viral genome however in this study I focused on the mutations located in ORF1A.  
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